|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
ISO |
Azacitidine inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA] |
CTD |
PMID:22841775 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Adamts1 |
ADAM metallopeptidase with thrombospondin type 1 motif, 1 |
decreases expression |
ISO |
Azacitidine results in decreased expression of ADAMTS1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr11:24,932,227...24,941,068
Ensembl chr11:24,931,761...24,941,103
|
|
G |
Adrb1 |
adrenoceptor beta 1 |
affects expression |
ISO |
Azacitidine affects the expression of ADRB1 mRNA |
CTD |
PMID:19002953 |
|
NCBI chr 1:255,772,217...255,773,617
Ensembl chr 1:255,771,597...255,807,259
|
|
G |
Adrb2 |
adrenoceptor beta 2 |
affects expression multiple interactions |
ISO |
Azacitidine affects the expression of ADRB2 mRNA Azacitidine inhibits the reaction [Particulate Matter results in decreased expression of ADRB2 mRNA] |
CTD |
PMID:19002953 PMID:30986742 |
|
NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512
|
|
G |
Afp |
alpha-fetoprotein |
increases expression |
ISO |
Azacitidine results in increased expression of AFP mRNA |
CTD |
PMID:27590069 |
|
NCBI chr14:17,573,412...17,591,476
Ensembl chr14:17,573,412...17,591,480
|
|
G |
Aggf1 |
angiogenic factor with G patch and FHA domains 1 |
increases expression |
ISO |
Azacitidine results in increased expression of AGGF1 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 2:26,619,336...26,646,050
Ensembl chr 2:26,619,339...26,645,952
|
|
G |
Ahr |
aryl hydrocarbon receptor |
increases expression multiple interactions |
ISO |
Azacitidine results in increased expression of AHR mRNA [Azacitidine co-treated with Butyrates] inhibits the reaction [Chromium inhibits the reaction [Benzo(a)pyrene promotes the reaction [AHR protein binds to CYP1A1 promoter]]]; Azacitidine inhibits the reaction [Chromium inhibits the reaction [Benzo(a)pyrene promotes the reaction [AHR protein binds to CYP1A1 promoter]]] |
CTD |
PMID:12927368 PMID:17682057 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Ak5 |
adenylate kinase 5 |
increases expression |
ISO |
Azacitidine results in increased expression of AK5 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:241,397,297...241,581,483
Ensembl chr 2:241,397,297...241,581,458
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
Azacitidine inhibits the reaction [TGFB1 protein results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:22841775 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alad |
aminolevulinate dehydratase |
decreases expression |
ISO |
Azacitidine results in decreased expression of ALAD mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 5:75,961,993...75,972,334
Ensembl chr 5:75,961,993...75,972,474
|
|
G |
Alb |
albumin |
decreases expression increases expression |
ISO |
Azacitidine results in decreased expression of ALB protein Azacitidine results in increased expression of ALB mRNA |
CTD |
PMID:27590069 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Aldh3a1 |
aldehyde dehydrogenase 3 family, member A1 |
multiple interactions |
ISO |
[Azacitidine co-treated with Butyrates] inhibits the reaction [Chromium inhibits the reaction [Benzo(a)pyrene results in increased expression of ALDH3A1 mRNA]]; Azacitidine inhibits the reaction [Chromium inhibits the reaction [Benzo(a)pyrene results in increased expression of ALDH3A1 mRNA]] |
CTD |
PMID:17682057 |
|
NCBI chr10:45,892,993...45,902,680
Ensembl chr10:45,892,924...45,902,681
|
|
G |
Anxa1 |
annexin A1 |
decreases expression |
EXP |
Azacitidine results in decreased expression of ANXA1 protein |
CTD |
PMID:17105402 |
|
NCBI chr 1:217,861,175...217,877,205
Ensembl chr 1:217,861,175...217,877,343
|
|
G |
App |
amyloid beta precursor protein |
decreases methylation multiple interactions |
ISO |
Azacitidine results in decreased methylation of APP promoter Azacitidine results in increased expression of and results in increased cleavage of APP protein; Betaine inhibits the reaction [Azacitidine results in decreased methylation of APP promoter]; Betaine inhibits the reaction [Azacitidine results in increased expression of and results in increased cleavage of APP protein] |
CTD |
PMID:19635394 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Aqp5 |
aquaporin 5 |
decreases methylation increases expression multiple interactions |
ISO |
Azacitidine results in decreased methylation of AQP5 promoter Azacitidine results in increased expression of AQP5 protein [Azacitidine results in decreased methylation of AQP5 promoter] which results in increased expression of AQP5 mRNA; Azacitidine promotes the reaction [SP1 protein binds to AQP5 promoter] |
CTD |
PMID:17198683 |
|
NCBI chr 7:130,722,675...130,726,207
Ensembl chr 7:130,721,748...130,726,209
|
|
G |
Aqp9 |
aquaporin 9 |
multiple interactions increases expression |
ISO |
[Azacitidine results in increased expression of AQP9 mRNA] which results in increased uptake of arsenic trioxide; HNF1A mutant form inhibits the reaction [Azacitidine results in increased expression of AQP9 mRNA] |
CTD |
PMID:25953102 |
|
NCBI chr 8:71,797,231...71,837,485
Ensembl chr 8:71,797,234...71,837,395
|
|
G |
Ar |
androgen receptor |
multiple interactions increases expression |
ISO |
[Azacitidine analog results in increased expression of AR protein] which results in increased susceptibility to bicalutamide; [Azacitidine analog results in increased expression of AR protein] which results in increased susceptibility to Dihydrotestosterone |
CTD |
PMID:18324645 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Arhgap35 |
Rho GTPase activating protein 35 |
increases expression |
ISO |
Azacitidine results in increased expression of ARHGAP35 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 1:77,202,436...77,319,298
Ensembl chr 1:77,202,436...77,319,298
|
|
G |
Arhgef2 |
Rho/Rac guanine nucleotide exchange factor 2 |
decreases expression |
ISO |
Azacitidine results in decreased expression of ARHGEF2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:174,061,126...174,118,355
Ensembl chr 2:174,062,976...174,118,355
|
|
G |
Art1 |
ADP-ribosyltransferase 1 |
increases expression |
ISO |
Azacitidine results in increased expression of ART1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 1:156,478,096...156,487,172
Ensembl chr 1:156,482,621...156,487,172
|
|
G |
Asb2 |
ankyrin repeat and SOCS box-containing 2 |
increases expression |
ISO |
Azacitidine results in increased expression of ASB2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 6:122,474,754...122,511,014
Ensembl chr 6:122,474,756...122,510,854
|
|
G |
Atp2b1 |
ATPase plasma membrane Ca2+ transporting 1 |
decreases expression |
ISO |
Azacitidine results in decreased expression of ATP2B1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 7:33,735,595...33,845,226
Ensembl chr 7:33,735,871...33,843,295
|
|
G |
Atp6v0c |
ATPase H+ transporting V0 subunit C |
increases expression |
ISO |
Azacitidine results in increased expression of ATP6V0C mRNA |
CTD |
PMID:20823114 |
|
NCBI chr10:13,196,204...13,202,580
Ensembl chr10:13,196,204...13,201,500
|
|
G |
Aurka |
aurora kinase A |
multiple interactions |
ISO |
[Azacitidine co-treated with Thalidomide] affects the expression of AURKA mRNA |
CTD |
PMID:18720364 |
|
NCBI chr 3:161,128,309...161,144,524
Ensembl chr 3:161,128,313...161,144,390
|
|
G |
Bad |
BCL2-associated agonist of cell death |
increases expression multiple interactions |
EXP |
Azacitidine results in increased expression of BAD mRNA [Azacitidine co-treated with entinostat] results in increased expression of BAD mRNA |
CTD |
PMID:21224363 |
|
NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823
|
|
G |
Bak1 |
BCL2-antagonist/killer 1 |
multiple interactions increases expression |
EXP |
[Azacitidine co-treated with entinostat] results in increased expression of BAK1 mRNA Azacitidine results in increased expression of BAK1 mRNA |
CTD |
PMID:21224363 |
|
NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression |
ISO |
Bleomycin inhibits the reaction [Azacitidine results in increased expression of BAX mRNA] |
CTD |
PMID:32278510 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcat1 |
branched chain amino acid transaminase 1 |
decreases expression |
ISO |
Azacitidine results in decreased expression of BCAT1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:177,964,834...178,046,573
Ensembl chr 4:177,964,834...178,046,597
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases expression |
ISO |
Bleomycin inhibits the reaction [Azacitidine results in decreased expression of BCL2 mRNA]; Bleomycin inhibits the reaction [Azacitidine results in decreased expression of BCL2 protein] Azacitidine results in decreased expression of BCL2 mRNA; Azacitidine results in decreased expression of BCL2 protein |
CTD |
PMID:32278510 |
|
NCBI chr13:22,689,783...22,853,920
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions affects expression |
ISO |
[metacept-1 co-treated with Azacitidine] results in decreased expression of BCL2L1 [Azacitidine affects the expression of IL6R protein] which affects the expression of BCL2L1 protein |
CTD |
PMID:18443271 PMID:19148494 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Bcl2l13 |
Bcl2-like 13 |
increases expression |
ISO |
Azacitidine results in increased expression of BCL2L13 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:154,056,116...154,112,890
Ensembl chr 4:154,056,127...154,108,985
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
increases expression decreases methylation multiple interactions |
ISO |
Azacitidine results in increased expression of BDNF mRNA Azacitidine results in decreased methylation of BDNF promoter Tetrodotoxin inhibits the reaction [Azacitidine results in decreased methylation of BDNF promoter]; Tetrodotoxin inhibits the reaction [Azacitidine results in increased expression of BDNF mRNA] |
CTD |
PMID:18184782 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
decreases expression |
EXP |
Azacitidine results in decreased expression of BGLAP protein |
CTD |
PMID:18037191 |
|
NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495
|
|
G |
Bicd1 |
BICD cargo adaptor 1 |
decreases expression |
ISO |
Azacitidine results in decreased expression of BICD1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:182,479,071...182,631,504
Ensembl chr 4:182,479,071...182,627,434
|
|
G |
Bik |
BCL2-interacting killer |
multiple interactions increases expression |
EXP |
[Azacitidine co-treated with entinostat] results in increased expression of BIK mRNA Azacitidine results in increased expression of BIK mRNA |
CTD |
PMID:21224363 |
|
NCBI chr 7:114,672,277...114,691,296
Ensembl chr 7:114,672,277...114,691,296
|
|
G |
Bmp15 |
bone morphogenetic protein 15 |
increases expression |
ISO |
Azacitidine results in increased expression of BMP15 mRNA |
CTD |
PMID:23395740 |
|
NCBI chr X:16,169,123...16,174,187
Ensembl chr X:16,169,123...16,174,187
|
|
G |
Bnip3 |
BCL2 interacting protein 3 |
increases expression |
ISO |
Azacitidine results in increased expression of BNIP3 mRNA |
CTD |
PMID:25446377 |
|
NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359
|
|
G |
Bok |
BCL2 family apoptosis regulator BOK |
multiple interactions increases expression |
EXP |
[Azacitidine co-treated with entinostat] results in increased expression of BOK mRNA Azacitidine results in increased expression of BOK mRNA |
CTD |
PMID:21224363 |
|
NCBI chr 9:94,223,493...94,234,476
Ensembl chr 9:94,223,389...94,234,476
|
|
G |
Bub1b |
BUB1 mitotic checkpoint serine/threonine kinase B |
multiple interactions |
ISO |
[Azacitidine co-treated with Thalidomide] affects the expression of BUB1B mRNA |
CTD |
PMID:18720364 |
|
NCBI chr 3:105,563,089...105,615,547
Ensembl chr 3:105,563,138...105,615,547
|
|
G |
C3ar1 |
complement C3a receptor 1 |
increases expression |
ISO |
Azacitidine results in increased expression of C3AR1 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 4:156,074,747...156,084,680
Ensembl chr 4:156,075,389...156,084,701
|
|
G |
Calca |
calcitonin-related polypeptide alpha |
decreases methylation |
ISO |
Azacitidine results in decreased methylation of CALCA promoter |
CTD |
PMID:19299654 |
|
NCBI chr 1:168,878,212...168,883,176
Ensembl chr 1:168,878,214...168,883,105
|
|
G |
Cald1 |
caldesmon 1 |
increases expression |
ISO |
Azacitidine results in increased expression of CALD1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:63,265,781...63,446,936
Ensembl chr 4:63,265,942...63,446,932
|
|
G |
Casp3 |
caspase 3 |
affects expression increases expression multiple interactions |
ISO |
Azacitidine affects the expression of CASP3 protein Azacitidine results in increased expression of CASP3 mRNA [metacept-1 co-treated with Azacitidine] results in increased expression of CASP3 |
CTD |
PMID:18443271 PMID:19148494 PMID:23395740 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
increases expression |
ISO |
Azacitidine results in increased expression of CASP8 mRNA |
CTD |
PMID:18082045 PMID:23395740 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
increases expression |
ISO |
Azacitidine results in increased expression of CASP9 mRNA |
CTD |
PMID:23395740 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Ccna1 |
cyclin A1 |
multiple interactions decreases expression |
ISO |
Azacitidine inhibits the reaction [MECP2 protein binds to CCNA1 promoter]; Azacitidine promotes the reaction [H3-4 protein modified form binds to CCNA1 promoter]; Azacitidine promotes the reaction [H4-16 protein modified form binds to CCNA1 promoter] Azacitidine results in decreased expression of CCNA1 mRNA |
CTD |
PMID:17698632 |
|
NCBI chr 2:139,231,738...139,278,066
Ensembl chr 2:139,201,074...139,243,157
|
|
G |
Ccna2 |
cyclin A2 |
multiple interactions decreases expression |
ISO |
[Azacitidine co-treated with Thalidomide] affects the expression of CCNA2 mRNA Azacitidine results in decreased expression of CCNA2 mRNA |
CTD |
PMID:18720364 PMID:20823114 |
|
NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577
|
|
G |
Ccnb1 |
cyclin B1 |
multiple interactions increases expression |
ISO |
[Azacitidine co-treated with Thalidomide] affects the expression of CCNB1 mRNA Azacitidine results in increased expression of CCNB1 protein |
CTD |
PMID:18720364 PMID:20607034 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Ccnd1 |
cyclin D1 |
increases expression |
ISO |
Azacitidine results in increased expression of CCND1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccnd2 |
cyclin D2 |
affects methylation multiple interactions |
ISO |
Azacitidine affects the methylation of CCND2 promoter [Azacitidine affects the methylation of CCND2 promoter] which affects the expression of CCND2 mRNA |
CTD |
PMID:17016690 |
|
NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495
|
|
G |
Ccng2 |
cyclin G2 |
decreases expression |
ISO |
Azacitidine results in decreased expression of CCNG2 mRNA |
CTD |
PMID:21245298 |
|
NCBI chr14:14,804,321...14,812,819
Ensembl chr14:14,804,322...14,812,830
|
|
G |
Cd274 |
CD274 molecule |
multiple interactions |
ISO |
Azacitidine inhibits the reaction [Oleanolic Acid inhibits the reaction [IL1B protein results in increased expression of CD274 mRNA]]; Azacitidine inhibits the reaction [Oleanolic Acid inhibits the reaction [IL1B protein results in increased expression of CD274 protein]] |
CTD |
PMID:32894642 |
|
NCBI chr 1:227,116,627...227,137,379
Ensembl chr 1:227,116,649...227,134,450
|
|
G |
Cdc20 |
cell division cycle 20 |
multiple interactions |
ISO |
[Azacitidine co-treated with Thalidomide] affects the expression of CDC20 mRNA |
CTD |
PMID:18720364 |
|
NCBI chr 5:131,966,203...131,970,406
Ensembl chr 5:131,966,215...131,970,512
|
|
G |
Cdc42bpa |
CDC42 binding protein kinase alpha |
decreases expression |
ISO |
Azacitidine results in decreased expression of CDC42BPA mRNA |
CTD |
PMID:20823114 |
|
NCBI chr13:91,683,775...91,903,732
Ensembl chr13:91,684,007...91,903,732
|
|
G |
Cdh1 |
cadherin 1 |
decreases methylation increases expression |
ISO |
Azacitidine results in decreased methylation of CDH1 promoter Azacitidine results in increased expression of CDH1 mRNA |
CTD |
PMID:17520682 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Cdh2 |
cadherin 2 |
increases expression |
EXP |
Azacitidine results in increased expression of CDH2 mRNA |
CTD |
PMID:18037191 |
|
NCBI chr18:7,776,704...7,990,934
Ensembl chr18:7,776,704...7,990,167
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
multiple interactions increases expression |
ISO |
[Azacitidine co-treated with Thalidomide] affects the expression of CDK1 mRNA Azacitidine analog results in increased expression of CDK1 protein |
CTD |
PMID:18324645 PMID:18720364 |
|
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases expression |
ISO |
Azacitidine analog results in decreased expression of CDK2 protein |
CTD |
PMID:18324645 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
decreases expression |
ISO |
Azacitidine analog results in decreased expression of CDK4 protein |
CTD |
PMID:18324645 |
|
NCBI chr 7:62,885,647...62,889,562
Ensembl chr 7:62,883,105...62,942,403
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression multiple interactions |
ISO EXP |
Azacitidine analog results in increased expression of CDKN1A protein; Azacitidine results in increased expression of CDKN1A mRNA [Azacitidine co-treated with entinostat] results in increased expression of CDKN1A mRNA; Azacitidine inhibits the reaction [potassium bromate results in increased expression of CDKN1A protein] [metacept-1 co-treated with Azacitidine] results in increased expression of CDKN1A |
CTD |
PMID:18324645 PMID:19148494 PMID:20823114 PMID:21224363 PMID:25015661 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1c |
cyclin-dependent kinase inhibitor 1C |
increases expression |
ISO |
Azacitidine results in increased expression of CDKN1C mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 1:198,655,394...198,658,097
Ensembl chr 1:198,655,407...198,658,048
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
multiple interactions decreases methylation affects methylation increases expression |
EXP ISO |
[Azacitidine co-treated with entinostat] results in decreased methylation of CDKN2A gene; [Azacitidine co-treated with entinostat] results in increased expression of CDKN2A mRNA Azacitidine inhibits the reaction [Particulate Matter results in increased methylation of CDKN2A promoter] Hydroxyurea inhibits the reaction [Azacitidine results in decreased methylation of CDKN2A gene] Azacitidine affects the methylation of CDKN2A gene Azacitidine results in increased expression of CDKN2A mRNA |
CTD |
PMID:17686055 PMID:18443271 PMID:21224363 PMID:22355787 |
|
NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149
|
|
G |
Cdkn2b |
cyclin-dependent kinase inhibitor 2B |
decreases methylation multiple interactions affects response to substance |
ISO |
Azacitidine results in decreased methylation of CDKN2B promoter [metacept-1 co-treated with Azacitidine] results in increased expression of CDKN2B CDKN2B promoter modified form affects the susceptibility to Azacitidine |
CTD |
PMID:17611569 PMID:19148494 PMID:19194470 |
|
NCBI chr 5:104,009,839...104,019,082
Ensembl chr 5:104,010,680...104,019,050
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
decreases methylation increases expression |
ISO |
Azacitidine results in decreased methylation of CEBPA promoter Azacitidine results in increased expression of CEBPA mRNA |
CTD |
PMID:19194470 PMID:27590069 |
|
NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412
|
|
G |
Cenpa |
centromere protein A |
multiple interactions |
ISO |
[Azacitidine co-treated with Thalidomide] affects the expression of CENPA mRNA |
CTD |
PMID:18720364 |
|
NCBI chr 6:25,700,142...25,711,767
Ensembl chr 6:25,700,142...25,711,675
|
|
G |
Cenpf |
centromere protein F |
multiple interactions |
ISO |
[Azacitidine co-treated with Thalidomide] affects the expression of CENPF mRNA |
CTD |
PMID:18720364 |
|
NCBI chr13:101,184,127...101,229,714
Ensembl chr13:101,184,127...101,229,669
|
|
G |
Cenpo |
centromere protein O |
increases expression |
ISO |
Azacitidine results in increased expression of CENPO mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 6:27,203,642...27,218,394
Ensembl chr 6:27,188,537...27,218,314
|
|
G |
Chat |
choline O-acetyltransferase |
increases expression |
ISO |
Azacitidine results in increased expression of CHAT mRNA; Azacitidine results in increased expression of CHAT protein |
CTD |
PMID:19151599 |
|
NCBI chr16:7,657,362...7,717,093
Ensembl chr16:7,657,362...7,717,093
|
|
G |
Chga |
chromogranin A |
decreases expression |
ISO |
Azacitidine results in decreased expression of CHGA protein |
CTD |
PMID:20607034 |
|
NCBI chr 6:121,696,051...121,707,399
Ensembl chr 6:121,696,051...121,707,398
|
|
G |
Chit1 |
chitinase 1 |
increases expression |
ISO |
Azacitidine results in increased expression of CHIT1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr13:45,565,841...45,613,593
Ensembl chr13:45,593,845...45,613,592
|
|
G |
Chrm1 |
cholinergic receptor, muscarinic 1 |
affects expression |
ISO |
Azacitidine affects the expression of CHRM1 mRNA |
CTD |
PMID:19002953 |
|
NCBI chr 1:205,567,046...205,583,001
Ensembl chr 1:205,567,220...205,582,356
|
|
G |
Chrm2 |
cholinergic receptor, muscarinic 2 |
affects expression |
ISO |
Azacitidine affects the expression of CHRM2 mRNA |
CTD |
PMID:19002953 |
|
NCBI chr 4:65,015,408...65,149,104
Ensembl chr 4:65,014,144...65,149,103
|
|
G |
Chst14 |
carbohydrate sulfotransferase 14 |
increases expression |
EXP |
Azacitidine results in increased expression of CHST14 mRNA |
CTD |
PMID:27415467 |
|
NCBI chr 3:105,916,481...105,918,538
Ensembl chr 3:105,916,466...105,918,548
|
|
G |
Ciita |
class II, major histocompatibility complex, transactivator |
multiple interactions increases expression |
ISO |
[Azacitidine promotes the reaction [IFNG protein results in increased expression of CIITA mRNA]] which results in increased expression of HLA-DRA protein; [Azacitidine results in decreased methylation of CIITA promoter] promotes the reaction [IFNG protein results in increased expression of CIITA mRNA] Azacitidine results in increased expression of CIITA mRNA |
CTD |
PMID:18829986 PMID:20823114 |
|
NCBI chr10:5,139,947...5,187,493
Ensembl chr10:5,140,178...5,187,440
|
|
G |
Cldn10 |
claudin 10 |
decreases expression |
ISO |
Azacitidine results in decreased expression of CLDN10 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr15:95,862,785...95,954,526
Ensembl chr15:95,862,760...95,954,526
|
|
G |
Cldn6 |
claudin 6 |
increases expression decreases methylation multiple interactions |
ISO |
Azacitidine results in increased expression of CLDN6 mRNA Azacitidine results in decreased methylation of CLDN6 promoter [trichostatin A co-treated with Azacitidine] results in decreased methylation of CLDN6 promoter |
CTD |
PMID:18661270 |
|
NCBI chr10:12,710,302...12,713,987
Ensembl chr10:12,709,960...12,715,973
|
|
G |
Cldn8 |
claudin 8 |
increases expression |
ISO |
Azacitidine results in increased expression of CLDN8 mRNA |
CTD |
PMID:18661270 |
|
NCBI chr11:27,875,857...27,878,106
Ensembl chr11:27,875,692...27,878,513
|
|
G |
Cldn9 |
claudin 9 |
decreases methylation multiple interactions increases expression |
ISO |
Azacitidine results in decreased methylation of CLDN9 promoter [trichostatin A co-treated with Azacitidine] results in decreased methylation of CLDN9 promoter Azacitidine results in increased expression of CLDN9 mRNA |
CTD |
PMID:18661270 |
|
NCBI chr10:12,714,137...12,715,568
|
|
G |
Cnnm2 |
cyclin and CBS domain divalent metal cation transport mediator 2 |
decreases expression |
ISO |
Azacitidine results in decreased expression of CNNM2 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 1:245,643,682...245,769,542
Ensembl chr 1:245,643,768...245,763,286
|
|
G |
Col14a1 |
collagen type XIV alpha 1 chain |
increases expression |
ISO |
Azacitidine results in increased expression of COL14A1 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 7:86,722,093...86,937,215
Ensembl chr 7:86,722,094...86,937,214
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions |
ISO |
Azacitidine inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA]; Azacitidine inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 protein] |
CTD |
PMID:22841775 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Col6a3 |
collagen type VI alpha 3 chain |
decreases expression |
ISO |
Azacitidine results in decreased expression of COL6A3 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 9:91,361,578...91,439,434
Ensembl chr 9:91,361,583...91,439,471
|
|
G |
Col9a3 |
collagen type IX alpha 3 chain |
decreases expression |
ISO |
Azacitidine results in decreased expression of COL9A3 mRNA |
CTD |
PMID:18033690 |
|
NCBI chr 3:167,711,776...167,734,468
Ensembl chr 3:167,711,840...167,734,465
|
|
G |
Cox6a2 |
cytochrome c oxidase subunit 6A2 |
increases expression |
ISO |
Azacitidine results in increased expression of COX6A2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 1:182,788,528...182,790,746
Ensembl chr 1:182,788,528...182,789,274
|
|
G |
Cpe |
carboxypeptidase E |
increases expression |
ISO |
Azacitidine results in increased expression of CPE mRNA |
CTD |
PMID:20823114 |
|
NCBI chr16:25,030,276...25,142,231
Ensembl chr16:25,030,276...25,142,233
|
|
G |
Cplx1 |
complexin 1 |
increases expression |
ISO |
Azacitidine results in increased expression of CPLX1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr14:1,184,638...1,216,392
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
ISO |
Azacitidine promotes the reaction [CREB1 protein modified form binds to PPP2CA promoter] |
CTD |
PMID:19155497 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Creb3l4 |
cAMP responsive element binding protein 3-like 4 |
increases expression |
EXP |
Azacitidine results in increased expression of CREB3L4 mRNA |
CTD |
PMID:27415467 |
|
NCBI chr 2:175,690,340...175,696,084
Ensembl chr 2:175,690,335...175,695,932
|
|
G |
Crem |
cAMP responsive element modulator |
decreases expression |
ISO |
Azacitidine results in decreased expression of CREM mRNA |
CTD |
PMID:20823114 |
|
NCBI chr17:54,238,889...54,305,989
Ensembl chr17:54,239,030...54,305,989
|
|
G |
Cryaa |
crystallin, alpha A |
increases expression |
EXP |
Azacitidine results in increased expression of CRYAA protein |
CTD |
PMID:17105402 |
|
NCBI chr20:9,783,605...9,787,351
Ensembl chr20:9,783,605...9,787,349
|
|
G |
Cryab |
crystallin, alpha B |
increases expression |
EXP |
Azacitidine results in increased expression of CRYAB protein |
CTD |
PMID:17105402 |
|
NCBI chr 8:51,093,441...51,099,161
Ensembl chr 8:51,093,441...51,099,157
|
|
G |
Csf1 |
colony stimulating factor 1 |
increases expression |
EXP |
Azacitidine results in increased expression of CSF1 mRNA |
CTD |
PMID:17156202 |
|
NCBI chr 2:195,377,215...195,396,608
Ensembl chr 2:195,377,215...195,411,704
|
|
G |
Csn1s1 |
casein alpha s1 |
increases expression |
ISO |
Azacitidine results in increased expression of CSN1S1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr14:20,343,620...20,359,614
Ensembl chr14:20,343,619...20,359,614
|
|
G |
Cst3 |
cystatin C |
increases expression |
ISO |
Azacitidine results in increased expression of CST3 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 3:136,336,923...136,340,796
Ensembl chr 3:136,336,920...136,340,822
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
decreases methylation increases expression |
ISO |
Azacitidine results in decreased methylation of CXCL12 promoter Azacitidine results in increased expression of CXCL12 mRNA; Azacitidine results in increased expression of CXCL12 protein |
CTD |
PMID:19748759 |
|
NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions increases expression |
ISO |
Azacitidine promotes the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]; Azacitidine promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA] [Azacitidine co-treated with Butyrates] inhibits the reaction [Chromium inhibits the reaction [Benzo(a)pyrene promotes the reaction [AHR protein binds to CYP1A1 promoter]]]; [Azacitidine co-treated with Butyrates] inhibits the reaction [Chromium inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA]]; Azacitidine inhibits the reaction [Chromium inhibits the reaction [Benzo(a)pyrene promotes the reaction [AHR protein binds to CYP1A1 promoter]]]; Azacitidine inhibits the reaction [Chromium inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA]] Azacitidine results in increased expression of CYP1A1 mRNA |
CTD |
PMID:11281733 PMID:12927368 PMID:17682057 PMID:27590069 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions increases expression |
ISO |
Azacitidine promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A2 mRNA] Azacitidine results in increased expression of CYP1A2 mRNA |
CTD |
PMID:12927368 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
multiple interactions increases expression |
ISO |
Azacitidine promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1B1 mRNA] Azacitidine results in increased expression of CYP1B1 mRNA |
CTD |
PMID:12927368 PMID:27590069 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
increases expression |
ISO |
Azacitidine results in increased expression of CYP3A4 mRNA |
CTD |
PMID:27590069 |
|
NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyth1 |
cytohesin 1 |
increases expression |
ISO |
Azacitidine results in increased expression of CYTH1 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr10:103,402,727...103,485,826
Ensembl chr10:103,366,145...103,485,760
|
|
G |
Dapk1 |
death associated protein kinase 1 |
affects methylation |
ISO |
Azacitidine affects the methylation of DAPK1 promoter |
CTD |
PMID:17557868 |
|
NCBI chr17:3,930,223...4,090,991
Ensembl chr17:3,930,213...4,090,991
|
|
G |
Dcn |
decorin |
multiple interactions decreases expression |
ISO |
Azacitidine promotes the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of DCN protein] Azacitidine results in decreased expression of DCN mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 7:32,281,252...32,321,291
Ensembl chr 7:32,281,252...32,321,270
|
|
G |
Des |
desmin |
increases expression multiple interactions |
EXP ISO |
Azacitidine results in increased expression of DES mRNA; Azacitidine results in increased expression of DES protein [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate co-treated with Azacitidine] results in increased expression of DES mRNA |
CTD |
PMID:18037191 PMID:20823114 |
|
NCBI chr 9:76,850,979...76,858,695
Ensembl chr 9:76,850,982...76,858,699
|
|
G |
Dhx9 |
DExH-box helicase 9 |
decreases expression |
ISO |
Azacitidine results in decreased expression of DHX9 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr13:65,602,322...65,639,098
Ensembl chr13:65,602,323...65,639,069
|
|
G |
Dio2 |
iodothyronine deiodinase 2 |
decreases expression |
ISO |
Azacitidine results in decreased expression of DIO2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 6:109,665,523...109,679,809
Ensembl chr 6:109,665,523...109,679,809
|
|
G |
Dlk1 |
delta like non-canonical Notch ligand 1 |
decreases methylation |
ISO |
Azacitidine results in decreased methylation of DLK1 promoter |
CTD |
PMID:19194470 |
|
NCBI chr 6:128,410,216...128,417,518
Ensembl chr 6:128,410,316...128,417,522
|
|
G |
Dlx5 |
distal-less homeobox 5 |
increases expression |
ISO |
Azacitidine results in increased expression of DLX5 mRNA |
CTD |
PMID:17085970 |
|
NCBI chr 4:34,999,139...35,003,504
Ensembl chr 4:34,999,139...35,003,407
|
|
G |
Dlx6 |
distal-less homeobox 6 |
increases expression |
ISO |
Azacitidine results in increased expression of DLX6 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:34,984,264...34,989,926
Ensembl chr 4:34,984,232...34,991,343
|
|
G |
Dnmt1 |
DNA methyltransferase 1 |
multiple interactions decreases expression |
ISO EXP |
[SLC28A1 protein results in increased uptake of Azacitidine] which results in decreased expression of DNMT1 protein; Arsenic Trioxide promotes the reaction [Azacitidine results in decreased expression of DNMT1 protein] [Azacitidine co-treated with entinostat] results in decreased expression of DNMT1 protein; [Cisplatin co-treated with Azacitidine] results in decreased expression of DNMT1 protein |
CTD |
PMID:19139132 PMID:19723570 PMID:21224363 PMID:28901456 |
|
NCBI chr 8:19,440,611...19,486,659
Ensembl chr 8:19,440,611...19,486,659
|
|
G |
Dpyd |
dihydropyrimidine dehydrogenase |
decreases methylation multiple interactions decreases response to substance |
ISO |
Azacitidine results in decreased methylation of DPYD promoter [Azacitidine results in decreased methylation of DPYD promoter] which results in increased expression of DPYD mRNA DPYD protein results in decreased susceptibility to Azacitidine |
CTD |
PMID:15501990 |
|
NCBI chr 2:206,609,043...207,474,982
Ensembl chr 2:206,609,122...207,474,982
|
|
G |
Dusp1 |
dual specificity phosphatase 1 |
increases expression |
ISO |
Azacitidine results in increased expression of DUSP1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr10:16,680,489...16,683,276
|
|
G |
Dusp6 |
dual specificity phosphatase 6 |
increases expression |
ISO |
Azacitidine results in increased expression of DUSP6 mRNA |
CTD |
PMID:21245298 |
|
NCBI chr 7:34,092,848...34,097,186
Ensembl chr 7:34,092,943...34,097,185
|
|
G |
E2f1 |
E2F transcription factor 1 |
multiple interactions |
ISO |
E2F1 protein affects the reaction [Azacitidine results in decreased activity of TERT protein]; E2F1 protein affects the reaction [Azacitidine results in decreased expression of TERT mRNA] |
CTD |
PMID:19451745 |
|
NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361
|
|
G |
Eef1a1 |
eukaryotic translation elongation factor 1 alpha 1 |
decreases expression |
ISO |
Azacitidine results in decreased expression of EEF1A1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 8:79,341,554...79,344,784
Ensembl chr 8:79,341,557...79,344,839
|
|
G |
Efna3 |
ephrin A3 |
increases expression |
ISO |
Azacitidine results in increased expression of EFNA3 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:174,729,192...174,738,111
Ensembl chr 2:174,729,764...174,738,736
|
|
G |
Egr2 |
early growth response 2 |
increases expression |
ISO |
Azacitidine results in increased expression of EGR2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr20:21,051,270...21,056,322
Ensembl chr20:21,051,277...21,055,562
|
|
G |
Eno2 |
enolase 2 |
decreases expression |
ISO |
Azacitidine results in decreased expression of ENO2 protein |
CTD |
PMID:20607034 |
|
NCBI chr 4:157,572,085...157,580,971
Ensembl chr 4:157,572,088...157,580,980
|
|
G |
Entpd1 |
ectonucleoside triphosphate diphosphohydrolase 1 |
increases expression |
ISO |
Azacitidine results in increased expression of ENTPD1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 1:239,425,515...239,552,323
Ensembl chr 1:239,425,430...239,552,317
|
|
G |
Esr1 |
estrogen receptor 1 |
increases expression |
ISO |
Azacitidine results in increased expression of ESR1 protein |
CTD |
PMID:22558281 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Ets1 |
ETS proto-oncogene 1, transcription factor |
multiple interactions |
ISO |
Azacitidine promotes the reaction [ETS1 protein binds to KIR2DL2 promoter]; Azacitidine promotes the reaction [ETS1 protein binds to KIR2DL4 promoter] |
CTD |
PMID:18945643 |
|
NCBI chr 8:31,045,909...31,168,010
Ensembl chr 8:31,045,945...31,168,010
|
|
G |
Eya1 |
EYA transcriptional coactivator and phosphatase 1 |
decreases expression |
ISO |
Azacitidine results in decreased expression of EYA1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 5:4,863,501...5,101,483
Ensembl chr 5:4,955,543...5,101,483
|
|
G |
Fads2 |
fatty acid desaturase 2 |
decreases expression |
ISO |
Azacitidine results in decreased expression of FADS2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 1:206,707,384...206,747,333
Ensembl chr 1:206,708,783...206,748,789
|
|
G |
Fam8a1 |
family with sequence similarity 8, member A1 |
increases expression |
ISO |
Azacitidine results in increased expression of FAM8A1 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr17:18,026,601...18,035,509
Ensembl chr17:18,026,601...18,035,470
|
|
G |
Faslg |
Fas ligand |
increases response to substance |
ISO |
Azacitidine results in increased susceptibility to FASLG protein |
CTD |
PMID:18829727 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Fbln1 |
fibulin 1 |
increases expression |
ISO |
Azacitidine results in increased expression of FBLN1 mRNA |
CTD |
PMID:21245298 |
|
NCBI chr 7:116,310,582...116,390,075
Ensembl chr 7:116,310,582...116,390,075
|
|
G |
Fen1 |
flap structure-specific endonuclease 1 |
multiple interactions |
ISO |
[Azacitidine co-treated with Thalidomide] affects the expression of FEN1 mRNA |
CTD |
PMID:18720364 |
|
NCBI chr 1:206,845,126...206,849,821
Ensembl chr 1:206,844,884...206,850,003
|
|
G |
Fgf7 |
fibroblast growth factor 7 |
decreases expression |
ISO |
Azacitidine results in decreased expression of FGF7 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 3:113,280,448...113,333,279
Ensembl chr 3:113,281,283...113,332,929
|
|
G |
Filip1l |
filamin A interacting protein 1-like |
decreases expression |
ISO |
Azacitidine results in decreased expression of FILIP1L mRNA |
CTD |
PMID:20823114 |
|
NCBI chr11:42,937,353...43,177,085
Ensembl chr11:42,940,467...43,177,415
|
|
G |
Foxo1 |
forkhead box O1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate co-treated with Azacitidine] results in increased expression of FOXO1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790
|
|
G |
Foxp3 |
forkhead box P3 |
multiple interactions |
ISO |
[Azacitidine co-treated with TGFB1 protein] results in increased expression of FOXP3 protein; [Azacitidine results in decreased methylation of FOXP3 gene] which results in increased expression of FOXP3 protein |
CTD |
PMID:18493985 |
|
NCBI chr X:14,908,494...14,924,994
Ensembl chr X:14,908,494...14,923,838
|
|
G |
Ftl1 |
ferritin light chain 1 |
decreases expression |
EXP |
Azacitidine results in decreased expression of FTL1 protein |
CTD |
PMID:17105402 |
|
NCBI chr 1:95,936,390...95,938,234
Ensembl chr 1:95,936,387...95,939,725
|
|
G |
Fyn |
FYN proto-oncogene, Src family tyrosine kinase |
increases expression |
ISO |
Azacitidine results in increased expression of FYN mRNA |
CTD |
PMID:21245298 |
|
NCBI chr20:42,767,733...42,960,903
Ensembl chr20:42,766,369...42,959,911
|
|
G |
Gabrb1 |
gamma-aminobutyric acid type A receptor subunit beta1 |
increases expression |
ISO |
Azacitidine results in increased expression of GABRB1 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr14:36,068,725...36,548,946
Ensembl chr14:36,080,393...36,548,948
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
decreases methylation multiple interactions increases expression |
ISO |
Azacitidine results in decreased methylation of GADD45A promoter [Azacitidine results in increased expression of GADD45A protein] which results in increased susceptibility to docetaxel Azacitidine results in increased expression of GADD45A mRNA; Azacitidine results in increased expression of GADD45A protein |
CTD |
PMID:19190346 |
|
NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115
|
|
G |
Gadd45b |
growth arrest and DNA-damage-inducible, beta |
multiple interactions |
ISO |
Azacitidine promotes the reaction [Depsipeptides results in increased expression of GADD45B] |
CTD |
PMID:18225533 |
|
NCBI chr 7:8,778,004...8,780,306
Ensembl chr 7:8,778,007...8,780,046
|
|
G |
Gata4 |
GATA binding protein 4 |
increases expression |
EXP |
Azacitidine results in increased expression of GATA4 mRNA; Azacitidine results in increased expression of GATA4 protein |
CTD |
PMID:18037191 |
|
NCBI chr15:37,459,601...37,531,291
Ensembl chr15:37,459,601...37,505,636
|
|
G |
Gbp2 |
guanylate binding protein 2 |
decreases expression |
ISO |
Azacitidine results in decreased expression of GBP2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:231,332,488...231,348,573
Ensembl chr 2:231,332,284...231,348,571
|
|
G |
Gcnt2 |
glucosaminyl (N-acetyl) transferase 2 |
decreases expression |
ISO |
Azacitidine results in decreased expression of GCNT2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr17:23,796,859...23,901,625 NCBI chr17:23,866,602...23,868,691
Ensembl chr17:23,796,859...23,901,611
|
|
G |
Gdf9 |
growth differentiation factor 9 |
increases expression |
ISO |
Azacitidine results in increased expression of GDF9 mRNA |
CTD |
PMID:23395740 |
|
NCBI chr10:37,589,200...37,599,970
Ensembl chr10:37,595,679...37,599,672
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
increases expression decreases expression |
EXP ISO |
Azacitidine results in increased expression of GJA1 protein Azacitidine results in decreased expression of GJA1 mRNA |
CTD |
PMID:18037191 PMID:20823114 |
|
NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582
|
|
G |
Gng7 |
G protein subunit gamma 7 |
affects methylation |
ISO |
Azacitidine affects the methylation of GNG7 promoter |
CTD |
PMID:18219292 |
|
NCBI chr 7:8,697,458...8,761,239
Ensembl chr 7:8,697,521...8,761,240
|
|
G |
Gpkow |
G patch domain and KOW motifs |
increases expression |
ISO |
Azacitidine results in increased expression of GPKOW mRNA |
CTD |
PMID:20823114 |
|
NCBI chr X:14,791,601...14,806,384
Ensembl chr X:14,791,610...14,806,384
|
|
G |
Gpnmb |
glycoprotein nmb |
decreases expression |
ISO |
Azacitidine results in decreased expression of GPNMB mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:78,010,247...78,031,491
Ensembl chr 4:78,010,197...78,049,367
|
|
G |
Gpx3 |
glutathione peroxidase 3 |
increases expression |
ISO |
5-azacytidine increases expression of GPX3 mRNA in epithelial cells of stomach |
RGD |
PMID:16229808 |
RGD:151665354 |
NCBI chr10:39,028,624...39,036,695
Ensembl chr10:39,028,570...39,037,035
|
|
G |
Grin2b |
glutamate ionotropic receptor NMDA type subunit 2B |
decreases methylation |
ISO |
Azacitidine results in decreased methylation of GRIN2B gene |
CTD |
PMID:18618247 |
|
NCBI chr 4:168,580,824...169,044,110
Ensembl chr 4:168,599,546...169,042,279
|
|
G |
Guk1 |
guanylate kinase 1 |
increases expression |
ISO |
Azacitidine results in increased expression of GUK1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr10:43,971,514...43,988,658
Ensembl chr10:43,971,509...43,980,107
|
|
G |
Gzmb |
granzyme B |
multiple interactions |
ISO |
Azacitidine inhibits the reaction [IL2 protein results in increased secretion of GZMB protein] |
CTD |
PMID:19394699 |
|
NCBI chr15:30,343,361...30,346,792
Ensembl chr15:30,173,603...30,346,814
|
|
G |
H1f0 |
H1.0 linker histone |
increases expression |
ISO |
Azacitidine results in increased expression of H1-0 protein |
CTD |
PMID:16006241 |
|
NCBI chr 7:110,592,834...110,594,694
Ensembl chr 7:110,592,208...110,594,694
|
|
G |
H2ax |
H2A.X variant histone |
increases expression multiple interactions |
ISO EXP |
Azacitidine results in increased expression of H2AX protein Azacitidine inhibits the reaction [potassium bromate results in increased phosphorylation of H2AX protein] |
CTD |
PMID:17991895 PMID:25015661 |
|
NCBI chr 8:44,671,927...44,673,257
Ensembl chr 8:44,671,786...44,673,239
|
|
G |
H3f4 |
H3.4 histone |
multiple interactions |
ISO |
Azacitidine promotes the reaction [H3-4 protein modified form binds to CCNA1 promoter] |
CTD |
PMID:17698632 |
|
NCBI chr10:43,740,797...43,741,207
|
|
G |
H4f16 |
H4 histone 16 |
multiple interactions |
ISO |
Azacitidine promotes the reaction [H4-16 protein modified form binds to CCNA1 promoter] |
CTD |
PMID:17698632 |
|
|
|
G |
Hgd |
homogentisate 1, 2-dioxygenase |
increases expression |
ISO |
Azacitidine results in increased expression of HGD mRNA |
CTD |
PMID:20823114 |
|
NCBI chr11:63,086,750...63,138,325
Ensembl chr11:63,086,752...63,138,323
|
|
G |
Hgf |
hepatocyte growth factor |
increases expression |
ISO |
Azacitidine results in increased expression of HGF mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409
|
|
G |
Hhex |
hematopoietically expressed homeobox |
increases expression |
ISO |
Azacitidine results in increased expression of HHEX mRNA |
CTD |
PMID:27590069 |
|
NCBI chr 1:235,190,455...235,196,042
Ensembl chr 1:235,190,455...235,196,042
|
|
G |
Hmga1 |
high mobility group AT-hook 1 |
increases expression |
ISO |
Azacitidine results in increased expression of HMGA1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr20:5,611,088...5,618,755
Ensembl chr20:5,611,694...5,618,752
|
|
G |
Hmga2 |
high mobility group AT-hook 2 |
increases expression multiple interactions |
ISO |
Azacitidine results in increased expression of HMGA2 mRNA TP73 protein promotes the reaction [Azacitidine results in increased expression of HMGA2 mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr 7:55,877,145...55,998,813
Ensembl chr 7:55,880,112...55,994,784
|
|
G |
Hmgb1 |
high mobility group box 1 |
decreases expression multiple interactions |
ISO |
Azacitidine results in decreased expression of HMGB1 mRNA Azacitidine results in decreased expression of and results in increased secretion of HMGB1 protein; Bleomycin inhibits the reaction [Azacitidine results in decreased expression of and results in increased secretion of HMGB1 protein]; Bleomycin inhibits the reaction [Azacitidine results in decreased expression of HMGB1 mRNA] |
CTD |
PMID:32278510 |
|
NCBI chr12:5,973,062...5,978,565
Ensembl chr12:5,901,586...5,978,565
|
|
G |
Hnf1a |
HNF1 homeobox A |
decreases methylation multiple interactions increases expression |
ISO |
Azacitidine results in decreased methylation of HNF1A promoter HNF1A mutant form inhibits the reaction [Azacitidine results in increased expression of AQP9 mRNA] Azacitidine results in increased expression of HNF1A mRNA; Azacitidine results in increased expression of HNF1A protein |
CTD |
PMID:25953102 |
|
NCBI chr12:41,638,536...41,672,806
Ensembl chr12:41,645,587...41,672,104
|
|
G |
Hnf4a |
hepatocyte nuclear factor 4, alpha |
increases expression |
ISO |
Azacitidine results in increased expression of HNF4A mRNA |
CTD |
PMID:27590069 |
|
NCBI chr 3:152,186,787...152,248,320
Ensembl chr 3:152,186,787...152,248,320
|
|
G |
Hoxa1 |
homeobox A1 |
multiple interactions increases expression |
ISO |
Azacitidine inhibits the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of HOXA1 mRNA] Azacitidine results in increased expression of HOXA1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:81,255,814...81,258,504
Ensembl chr 4:81,255,883...81,258,504
|
|
G |
Hpgd |
15-hydroxyprostaglandin dehydrogenase |
decreases methylation multiple interactions increases expression |
ISO |
Azacitidine results in decreased methylation of HPGD gene trichostatin A promotes the reaction [Azacitidine results in increased expression of HPGD mRNA] |
CTD |
PMID:19584167 |
|
NCBI chr16:33,986,265...34,024,228
Ensembl chr16:33,986,266...34,024,228
|
|
G |
Hsd3b1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
affects expression |
ISO |
Azacitidine affects the expression of HSD3B1 mRNA |
CTD |
PMID:18033690 |
|
NCBI chr 2:186,169,864...186,175,984
Ensembl chr 2:186,169,863...186,175,999
|
|
G |
Hsf1 |
heat shock transcription factor 1 |
decreases activity |
ISO |
Azacitidine results in decreased activity of HSF1 protein |
CTD |
PMID:34170685 |
|
NCBI chr 7:108,196,040...108,223,011
Ensembl chr 7:108,196,056...108,223,011
|
|
G |
Id1 |
inhibitor of DNA binding 1, HLH protein |
increases expression |
ISO |
Azacitidine results in increased expression of ID1 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 3:141,210,666...141,212,420
Ensembl chr 3:141,211,267...141,212,419
|
|
G |
Id3 |
inhibitor of DNA binding 3, HLH protein |
increases expression |
ISO |
Azacitidine results in increased expression of ID3 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 5:148,372,784...148,374,353
Ensembl chr 5:148,372,762...148,374,349
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
[Azacitidine promotes the reaction [IFNG protein results in increased expression of CIITA mRNA]] which results in increased expression of HLA-DRA protein; [Azacitidine results in decreased methylation of CIITA promoter] promotes the reaction [IFNG protein results in increased expression of CIITA mRNA]; [Azacitidine results in increased expression of KIR2DL4 protein] which results in increased secretion of IFNG protein |
CTD |
PMID:18829986 PMID:18945643 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Igfbp1 |
insulin-like growth factor binding protein 1 |
multiple interactions increases expression |
ISO |
Azacitidine inhibits the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 mRNA]; Azacitidine promotes the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 protein] Azacitidine results in increased expression of IGFBP1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr14:82,047,415...82,052,482
Ensembl chr14:82,047,415...82,052,482
|
|
G |
Igfbp4 |
insulin-like growth factor binding protein 4 |
increases expression |
ISO |
Azacitidine results in increased expression of IGFBP4 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr10:83,995,253...84,007,272
Ensembl chr10:83,989,591...84,007,225
|
|
G |
Il12b |
interleukin 12B |
increases expression |
ISO |
Azacitidine results in increased expression of IL12B mRNA |
CTD |
PMID:20823114 |
|
NCBI chr10:28,888,832...28,903,796
Ensembl chr10:28,893,008...28,902,903
|
|
G |
Il1b |
interleukin 1 beta |
increases expression multiple interactions |
EXP ISO |
Azacitidine results in increased expression of IL1B mRNA Azacitidine inhibits the reaction [Oleanolic Acid inhibits the reaction [IL1B protein results in increased expression of CD274 mRNA]]; Azacitidine inhibits the reaction [Oleanolic Acid inhibits the reaction [IL1B protein results in increased expression of CD274 protein]] |
CTD |
PMID:17156202 PMID:32894642 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il2 |
interleukin 2 |
multiple interactions |
ISO |
Azacitidine inhibits the reaction [IL2 protein results in increased secretion of GZMB protein]; Azacitidine inhibits the reaction [IL2 protein results in increased secretion of PRF1 protein] |
CTD |
PMID:19394699 |
|
NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Il4 |
interleukin 4 |
affects methylation |
ISO |
Azacitidine affects the methylation of IL4 promoter |
CTD |
PMID:18158872 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il6 |
interleukin 6 |
affects secretion affects methylation |
ISO |
Azacitidine affects the secretion of IL6 protein Azacitidine affects the methylation of IL6 promoter |
CTD |
PMID:18158872 PMID:18443271 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Il6r |
interleukin 6 receptor |
affects expression multiple interactions |
ISO |
[Azacitidine affects the expression of IL6R protein] which affects the expression of BCL2L1 protein; Azacitidine affects the expression of IL6R mRNA [Azacitidine affects the expression of IL6R protein] which affects the phosphorylation of STAT3 protein |
CTD |
PMID:18443271 |
|
NCBI chr 2:175,289,157...175,347,719
Ensembl chr 2:175,298,686...175,347,536
|
|
G |
Isca1 |
iron-sulfur cluster assembly 1 |
increases expression |
ISO |
Azacitidine results in increased expression of ISCA1 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr17:4,905,291...4,917,955
Ensembl chr17:4,905,287...4,917,955
|
|
G |
Itgb1 |
integrin subunit beta 1 |
decreases expression |
ISO |
Azacitidine results in decreased expression of ITGB1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr19:56,705,123...56,753,199
Ensembl chr19:56,705,171...56,753,195
|
|
G |
Itgb2 |
integrin subunit beta 2 |
decreases expression |
ISO |
Azacitidine results in decreased expression of ITGB2 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr20:11,061,394...11,097,656
Ensembl chr20:11,061,430...11,097,600
|
|
G |
Itprid2 |
ITPR interacting domain containing 2 |
increases expression |
ISO |
Azacitidine results in increased expression of ITPRID2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 3:64,536,707...64,573,978
Ensembl chr 3:64,536,707...64,573,978
|
|
G |
Kdr |
kinase insert domain receptor |
increases expression |
EXP |
Azacitidine results in increased expression of KDR mRNA |
CTD |
PMID:18037191 |
|
NCBI chr14:32,217,871...32,261,018
Ensembl chr14:32,217,871...32,261,018
|
|
G |
Kif2c |
kinesin family member 2C |
multiple interactions |
ISO |
[Azacitidine co-treated with Thalidomide] affects the expression of KIF2C mRNA |
CTD |
PMID:18720364 |
|
NCBI chr 5:130,637,347...130,662,680
Ensembl chr 5:130,637,347...130,662,637
|
|
G |
Kir3dl1 |
killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1 |
increases expression decreases methylation |
ISO |
Azacitidine results in increased expression of KIR3DL1 mRNA; Azacitidine results in increased expression of KIR3DL1 protein Azacitidine results in decreased methylation of KIR3DL1 promoter |
CTD |
PMID:18945643 PMID:19394699 |
|
NCBI chr 1:69,715,529...69,754,050
Ensembl chr 1:69,715,535...69,754,050
|
|
G |
Klf6 |
Kruppel-like factor 6 |
increases expression multiple interactions |
ISO |
Azacitidine results in increased expression of KLF6 mRNA TP73 protein promotes the reaction [Azacitidine results in increased expression of KLF6 mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr17:64,539,456...64,548,451
Ensembl chr17:64,531,463...64,588,570
|
|
G |
Krt19 |
keratin 19 |
increases expression |
ISO |
Azacitidine results in increased expression of KRT19 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr10:85,075,835...85,080,552
Ensembl chr10:85,066,802...85,171,799
|
|
G |
Krt32 |
keratin 32 |
increases expression |
ISO |
Azacitidine results in increased expression of KRT32 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr10:85,013,555...85,020,534
Ensembl chr10:85,013,554...85,020,534
|
|
G |
Krt8 |
keratin 8 |
multiple interactions increases expression |
ISO |
Azacitidine inhibits the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of KRT8 mRNA] Azacitidine results in increased expression of KRT8 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 7:133,124,203...133,131,656
Ensembl chr 7:133,124,203...133,131,728
|
|
G |
Lama1 |
laminin subunit alpha 1 |
affects localization |
ISO |
Azacitidine affects the localization of LAMA1 protein |
CTD |
PMID:18033690 |
|
NCBI chr 9:107,692,770...107,816,847
Ensembl chr 9:107,692,770...107,817,478
|
|
G |
Lamb2 |
laminin subunit beta 2 |
increases expression |
ISO |
Azacitidine results in increased expression of LAMB2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 8:109,178,367...109,190,552
Ensembl chr 8:109,178,409...109,190,549
|
|
G |
Ldhb |
lactate dehydrogenase B |
increases expression |
ISO |
Azacitidine results in increased expression of LDHB mRNA |
CTD |
PMID:23437403 |
|
NCBI chr 4:175,428,382...175,446,403
Ensembl chr 4:175,428,385...175,446,403
|
|
G |
Lims1 |
LIM zinc finger domain containing 1 |
increases expression |
ISO |
Azacitidine results in increased expression of LIMS1 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr20:26,309,833...26,418,511
Ensembl chr20:26,309,895...26,418,500
|
|
G |
Litaf |
lipopolysaccharide-induced TNF factor |
decreases expression |
ISO |
Azacitidine results in decreased expression of LITAF mRNA |
CTD |
PMID:19194470 |
|
NCBI chr10:4,656,308...4,692,981
Ensembl chr10:4,625,552...4,692,763
|
|
G |
LOC100911664 |
uncharacterized LOC100911664 |
increases expression |
ISO |
Azacitidine results in increased expression of C6ORF62 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr17:40,256,211...40,267,851
Ensembl chr17:40,256,211...40,276,020
|
|
G |
LOC102553180 |
protocadherin alpha-1-like |
affects methylation |
ISO |
Azacitidine affects the methylation of PCDHA1 promoter |
CTD |
PMID:18204046 |
|
|
|
G |
LOC686035 |
similar to heat shock 70kDa protein 6 (HSP70B) |
increases expression |
ISO |
Azacitidine results in increased expression of HSPA6 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr13:83,271,340...83,275,267
|
|
G |
Ltb4r |
leukotriene B4 receptor |
decreases expression |
ISO |
Azacitidine results in decreased expression of LTB4R mRNA |
CTD |
PMID:20823114 |
|
NCBI chr15:29,263,126...29,265,716
|
|
G |
Lyz2 |
lysozyme 2 |
increases expression |
ISO |
Azacitidine results in increased expression of LYZ mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 7:52,906,810...52,912,154
Ensembl chr 7:52,906,811...52,912,106
|
|
G |
Mad1l1 |
mitotic arrest deficient 1 like 1 |
decreases expression |
ISO |
Azacitidine results in decreased expression of MAD1L1 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr12:14,320,892...14,630,750
Ensembl chr12:14,320,892...14,630,703
|
|
G |
Map1a |
microtubule-associated protein 1A |
decreases expression |
ISO |
Azacitidine results in decreased expression of MAP1A mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 3:108,263,217...108,283,936
Ensembl chr 3:108,263,151...108,282,899
|
|
G |
Map2k5 |
mitogen activated protein kinase kinase 5 |
decreases expression |
ISO |
Azacitidine results in decreased expression of MAP2K5 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 8:63,625,220...63,852,090
Ensembl chr 8:63,625,221...63,851,983
|
|
G |
Mapt |
microtubule-associated protein tau |
decreases expression |
ISO |
Azacitidine results in decreased expression of MAPT protein |
CTD |
PMID:16930453 |
|
NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129
|
|
G |
Mcm5 |
minichromosome maintenance complex component 5 |
multiple interactions |
ISO |
[Azacitidine co-treated with Thalidomide] affects the expression of MCM5 mRNA |
CTD |
PMID:18720364 |
|
NCBI chr19:13,483,030...13,504,389
Ensembl chr19:13,483,066...13,504,389
|
|
G |
Mdc1 |
mediator of DNA damage checkpoint 1 |
increases expression |
ISO |
Azacitidine results in increased expression of MDC1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr20:2,893,693...2,912,394
Ensembl chr20:2,895,505...2,910,240
|
|
G |
Mdm2 |
MDM2 proto-oncogene |
increases expression |
ISO |
Azacitidine results in increased expression of MDM2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915
|
|
G |
Mecp2 |
methyl CpG binding protein 2 |
multiple interactions |
ISO |
Azacitidine inhibits the reaction [MECP2 protein binds to CCNA1 promoter] |
CTD |
PMID:17698632 |
|
NCBI chr X:151,781,177...151,844,687
Ensembl chr X:151,789,930...151,844,689
|
|
G |
Mef2a |
myocyte enhancer factor 2a |
increases expression affects expression |
ISO |
Azacitidine results in increased expression of MEF2A Azacitidine affects the expression of MEF2A protein |
CTD |
PMID:12094073 PMID:19002953 |
|
NCBI chr 1:120,847,874...120,982,488
Ensembl chr 1:120,850,080...120,981,948
|
|
G |
Mef2d |
myocyte enhancer factor 2D |
affects expression increases expression |
ISO |
Azacitidine affects the expression of MEF2D protein Azacitidine results in increased expression of MEF2D |
CTD |
PMID:12094073 PMID:19002953 |
|
NCBI chr 2:173,606,054...173,635,620
Ensembl chr 2:173,606,490...173,634,457
|
|
G |
Megf6 |
multiple EGF-like-domains 6 |
decreases expression |
ISO |
Azacitidine results in decreased expression of MEGF6 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 5:164,738,272...164,839,142
Ensembl chr 5:164,738,352...164,839,139
|
|
G |
Mesd |
mesoderm development LRP chaperone |
decreases expression |
EXP |
Azacitidine results in decreased expression of MESD protein |
CTD |
PMID:17105402 |
|
NCBI chr 1:137,866,707...137,879,999
Ensembl chr 1:137,874,242...137,879,999
|
|
G |
Mfap2 |
microfibril associated protein 2 |
decreases expression |
ISO |
Azacitidine results in decreased expression of MFAP2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 5:153,312,068...153,320,266
Ensembl chr 5:153,314,711...153,320,259
|
|
G |
Mfge8 |
milk fat globule EGF and factor V/VIII domain containing |
affects expression |
ISO |
Azacitidine affects the expression of MFGE8 mRNA |
CTD |
PMID:18033690 |
|
NCBI chr 1:133,064,665...133,080,069
Ensembl chr 1:133,064,665...133,080,073
|
|
G |
Mgmt |
O-6-methylguanine-DNA methyltransferase |
increases expression decreases methylation |
ISO |
Azacitidine results in increased expression of MGMT mRNA Azacitidine results in decreased methylation of MGMT protein |
CTD |
PMID:7511991 PMID:12807730 |
|
NCBI chr 1:191,710,980...191,937,760
Ensembl chr 1:191,710,930...191,937,756
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
multiple interactions |
ISO |
[Azacitidine co-treated with Thalidomide] affects the expression of MKI67 mRNA |
CTD |
PMID:18720364 |
|
NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
|
|
G |
Mmp1 |
matrix metallopeptidase 1 |
increases expression |
ISO |
Azacitidine results in increased expression of MMP1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
ISO |
metacept-1 inhibits the reaction [Azacitidine results in increased expression of MMP9] |
CTD |
PMID:19148494 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Morf4l2 |
mortality factor 4 like 2 |
decreases expression |
ISO |
Azacitidine results in decreased expression of MORF4L2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr X:100,082,562...100,093,658
Ensembl chr X:100,082,404...100,093,728
|
|
G |
Mov10l1 |
Mov10 like RISC complex RNA helicase 1 |
increases expression |
ISO |
Azacitidine results in increased expression of MOV10L1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 7:120,070,171...120,135,406
Ensembl chr 7:120,070,135...120,134,765
|
|
G |
Msrb2 |
methionine sulfoxide reductase B2 |
increases expression |
ISO |
Azacitidine results in increased expression of MSRB2 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr17:81,974,378...82,000,044
Ensembl chr17:81,974,196...82,000,043
|
|
G |
Mthfd2 |
methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase |
decreases expression |
ISO |
Azacitidine results in decreased expression of MTHFD2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:115,811,135...115,822,663
Ensembl chr 4:115,811,139...115,822,608
|
|
G |
Mtrex |
Mtr4 exosome RNA helicase |
increases expression |
ISO |
Azacitidine results in increased expression of MTREX mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:44,500,326...44,560,624
Ensembl chr 2:44,461,444...44,560,627
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
decreases expression multiple interactions |
ISO |
Azacitidine analog results in decreased expression of MYC mRNA MYC protein affects the reaction [Azacitidine results in decreased activity of TERT protein]; MYC protein affects the reaction [Azacitidine results in decreased expression of TERT mRNA] |
CTD |
PMID:18045574 PMID:19451745 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Myf5 |
myogenic factor 5 |
increases expression |
ISO |
Azacitidine results in increased expression of MYF5 mRNA |
CTD |
PMID:18938140 |
|
NCBI chr 7:42,802,946...42,806,177
Ensembl chr 7:42,802,946...42,806,177
|
|
G |
Myh7 |
myosin heavy chain 7 |
increases expression |
EXP |
Azacitidine results in increased expression of MYH7 mRNA; Azacitidine results in increased expression of MYH7 protein |
CTD |
PMID:17105402 |
|
NCBI chr15:28,446,550...28,469,888
Ensembl chr15:28,446,550...28,468,217
|
|
G |
Myl2 |
myosin light chain 2 |
increases expression |
EXP |
Azacitidine results in increased expression of MYL2 mRNA |
CTD |
PMID:17105402 |
|
NCBI chr12:34,454,223...34,468,554
Ensembl chr12:34,454,218...34,468,983
|
|
G |
Myod1 |
myogenic differentiation 1 |
increases expression |
EXP ISO |
Azacitidine results in increased expression of MYOD1 mRNA |
CTD |
PMID:18037191 PMID:18938140 |
|
NCBI chr 1:96,884,864...96,887,574
Ensembl chr 1:96,884,948...96,887,554
|
|
G |
Myog |
myogenin |
increases expression |
ISO |
Azacitidine results in increased expression of MYOG mRNA |
CTD |
PMID:18938140 |
|
NCBI chr13:45,745,455...45,748,044
Ensembl chr13:45,745,436...45,748,039
|
|
G |
Ncam1 |
neural cell adhesion molecule 1 |
increases expression |
EXP |
Azacitidine results in increased expression of NCAM1 mRNA |
CTD |
PMID:18037191 |
|
NCBI chr 8:49,865,629...50,165,687
Ensembl chr 8:49,865,633...50,166,014
|
|
G |
Nefl |
neurofilament light chain |
increases expression |
ISO |
Azacitidine results in increased expression of NEFL mRNA |
CTD |
PMID:20823114 |
|
NCBI chr15:42,301,920...42,305,793
Ensembl chr15:42,301,916...42,305,793
|
|
G |
Nfatc1 |
nuclear factor of activated T-cells 1 |
increases expression |
ISO |
Azacitidine results in increased expression of NFATC1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr18:74,046,421...74,156,041
Ensembl chr18:74,046,904...74,156,028
|
|
G |
Niban1 |
niban apoptosis regulator 1 |
increases expression multiple interactions |
ISO |
Azacitidine results in increased expression of NIBAN1 mRNA TP73 protein promotes the reaction [Azacitidine results in increased expression of NIBAN1 mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr13:63,674,240...63,827,748
Ensembl chr13:63,674,171...63,827,729
|
|
G |
Nkx2-5 |
NK2 homeobox 5 |
increases expression |
ISO |
Azacitidine results in increased expression of NKX2-5 mRNA |
CTD |
PMID:18557828 |
|
NCBI chr10:16,340,428...16,347,004
Ensembl chr10:16,344,159...16,346,934
|
|
G |
Nlgn3 |
neuroligin 3 |
increases expression |
ISO |
Azacitidine results in increased expression of NLGN3 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr X:66,427,926...66,457,378
Ensembl chr X:66,429,458...66,451,876
|
|
G |
Nme2 |
NME/NM23 nucleoside diphosphate kinase 2 |
increases expression |
EXP |
Azacitidine results in increased expression of NME2 protein |
CTD |
PMID:17105402 |
|
NCBI chr10:78,898,097...78,903,600
Ensembl chr10:78,897,770...78,903,538
|
|
G |
Nmi |
N-myc (and STAT) interactor |
increases expression |
ISO |
Azacitidine results in increased expression of NMI mRNA |
CTD |
PMID:21245298 |
|
NCBI chr 3:36,415,607...36,439,716
Ensembl chr 3:36,415,607...36,439,498
|
|
G |
Nom1 |
nucleolar protein with MIF4G domain 1 |
decreases expression |
ISO |
Azacitidine results in decreased expression of NOM1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:5,891,220...5,910,741
Ensembl chr 4:5,892,909...5,909,709
|
|
G |
Nphp1 |
nephrocystin 1 |
increases expression |
ISO |
Azacitidine results in increased expression of NPHP1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 3:114,960,650...115,016,234
Ensembl chr 3:114,960,650...115,016,234
|
|
G |
Nppa |
natriuretic peptide A |
increases expression |
ISO |
Azacitidine results in increased expression of NPPA |
CTD |
PMID:15005238 |
|
NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351
|
|
G |
Nppb |
natriuretic peptide B |
increases expression |
ISO |
Azacitidine results in increased expression of NPPB |
CTD |
PMID:15005238 |
|
NCBI chr 5:158,416,813...158,418,175
Ensembl chr 5:158,416,866...158,418,168
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
ISO |
[Azacitidine co-treated with Butyrates] inhibits the reaction [Chromium inhibits the reaction [Benzo(a)pyrene results in increased expression of NQO1 mRNA]]; Azacitidine inhibits the reaction [Chromium inhibits the reaction [Benzo(a)pyrene results in increased expression of NQO1 mRNA]] |
CTD |
PMID:17682057 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr4a1 |
nuclear receptor subfamily 4, group A, member 1 |
multiple interactions |
ISO |
[metacept-1 co-treated with Azacitidine] results in increased expression of NR4A1 |
CTD |
PMID:19148494 |
|
NCBI chr 7:132,368,399...132,389,300
Ensembl chr 7:132,374,840...132,389,297
|
|
G |
Nrip1 |
nuclear receptor interacting protein 1 |
decreases expression |
ISO |
Azacitidine results in decreased expression of NRIP1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr11:14,895,843...14,979,490
Ensembl chr11:14,895,553...14,981,761
|
|
G |
Nrn1 |
neuritin 1 |
decreases expression |
ISO |
Azacitidine results in decreased expression of NRN1 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr17:28,129,969...28,138,898
Ensembl chr17:28,129,977...28,138,896
|
|
G |
Nt5e |
5' nucleotidase, ecto |
increases expression |
ISO |
Azacitidine results in increased expression of NT5E mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 8:89,271,046...89,314,918
Ensembl chr 8:89,270,696...89,314,881
|
|
G |
Nts |
neurotensin |
decreases expression |
ISO |
Azacitidine results in decreased expression of NTS mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 7:37,564,944...37,574,350
Ensembl chr 7:37,564,533...37,574,423
|
|
G |
Nusap1 |
nucleolar and spindle associated protein 1 |
multiple interactions |
ISO |
[Azacitidine co-treated with Thalidomide] affects the expression of NUSAP1 mRNA |
CTD |
PMID:18720364 |
|
NCBI chr 3:106,603,273...106,633,624
Ensembl chr 3:106,603,289...106,633,624
|
|
G |
Nxt2 |
nuclear transport factor 2-like export factor 2 |
increases expression |
ISO |
Azacitidine results in increased expression of NXT2 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr X:105,855,616...105,862,902
Ensembl chr X:105,855,608...105,862,899
|
|
G |
Ocln |
occludin |
increases expression |
ISO |
Azacitidine results in increased expression of OCLN mRNA |
CTD |
PMID:18661270 |
|
NCBI chr 2:31,657,217...31,707,466
Ensembl chr 2:31,657,220...31,764,150
|
|
G |
Ogfrl1 |
opioid growth factor receptor-like 1 |
increases expression |
ISO |
Azacitidine results in increased expression of OGFRL1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 9:25,828,865...25,842,424
Ensembl chr 9:25,828,869...25,842,352
|
|
G |
Ogg1 |
8-oxoguanine DNA glycosylase |
decreases expression decreases methylation |
ISO |
Azacitidine results in decreased expression of OGG1 protein Azacitidine results in decreased methylation of OGG1 promoter |
CTD |
PMID:22064374 |
|
NCBI chr 4:146,474,701...146,481,959
Ensembl chr 4:146,474,750...146,484,766
|
|
G |
Olr1201 |
olfactory receptor 1201 |
increases expression |
ISO |
Azacitidine results in increased expression of OR8B8 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 8:37,693,578...37,694,510
Ensembl chr 8:37,693,499...37,694,547
|
|
G |
Oxr1 |
oxidation resistance 1 |
increases expression |
ISO |
Azacitidine results in increased expression of OXR1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 7:72,528,782...72,965,666
Ensembl chr 7:72,528,786...72,965,666
|
|
G |
Oxtr |
oxytocin receptor |
decreases expression |
ISO |
Azacitidine results in decreased expression of OXTR mRNA |
CTD |
PMID:21245298 |
|
NCBI chr 4:145,598,549...145,614,674
Ensembl chr 4:145,599,561...145,614,674
|
|
G |
P4hb |
prolyl 4-hydroxylase subunit beta |
increases expression |
EXP ISO |
Azacitidine results in increased expression of P4HB protein Azacitidine results in increased expression of P4HB mRNA |
CTD |
PMID:17105402 PMID:20823114 |
|
NCBI chr10:105,836,972...105,848,583
Ensembl chr10:105,836,982...105,848,500
|
|
G |
Paep |
progestagen associated endometrial protein |
decreases expression |
ISO |
Azacitidine results in decreased expression of PAEP mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 3:8,531,136...8,534,430
Ensembl chr 3:8,531,138...8,534,430
|
|
G |
Pak1 |
p21 (RAC1) activated kinase 1 |
increases expression |
ISO |
Azacitidine results in increased expression of PAK1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 1:152,111,172...152,226,390
Ensembl chr 1:152,111,188...152,226,383
|
|
G |
Pank3 |
pantothenate kinase 3 |
decreases expression |
ISO |
Azacitidine results in decreased expression of PANK3 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr10:20,229,129...20,252,955
Ensembl chr10:20,229,129...20,252,955
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage multiple interactions |
ISO |
Azacitidine results in increased cleavage of PARP1 protein Bleomycin inhibits the reaction [Azacitidine results in increased cleavage of PARP1 protein] |
CTD |
PMID:32278510 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pax4 |
paired box 4 |
increases expression |
ISO |
Azacitidine results in increased expression of PAX4 mRNA |
CTD |
PMID:18949370 |
|
NCBI chr 4:57,058,453...57,065,995
Ensembl chr 4:57,058,462...57,063,408
|
|
G |
Pcdh10 |
protocadherin 10 |
affects methylation |
ISO |
Azacitidine affects the methylation of PCDHA12 promoter |
CTD |
PMID:18204046 |
|
NCBI chr 2:128,617,212...128,683,354
Ensembl chr 2:128,617,174...128,677,190
|
|
G |
Pcdh18 |
protocadherin 18 |
decreases expression |
ISO |
Azacitidine results in decreased expression of PCDH18 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:133,831,996...133,845,992
Ensembl chr 2:133,832,001...133,845,883
|
|
G |
Pcdha1 |
protocadherin alpha 1 |
affects methylation |
ISO |
Azacitidine affects the methylation of PCDHA1 promoter |
CTD |
PMID:18204046 |
|
Ensembl chr18:28,581,225...28,846,211
|
|
G |
Pcdha10 |
protocadherin alpha 10 |
affects methylation |
ISO |
Azacitidine affects the methylation of PCDHA10 promoter |
CTD |
PMID:18204046 |
|
|
|
G |
Pcdha11 |
protocadherin alpha 11 |
affects methylation |
ISO |
Azacitidine affects the methylation of PCDHA11 promoter |
CTD |
PMID:18204046 |
|
|
|
G |
Pcdha2 |
protocadherin alpha 2 |
affects methylation |
ISO |
Azacitidine affects the methylation of PCDHA2 promoter |
CTD |
PMID:18204046 |
|
Ensembl chr18:28,581,225...28,846,211
|
|
G |
Pcdha3 |
protocadherin alpha 3 |
affects methylation |
ISO |
Azacitidine affects the methylation of PCDHA3 promoter |
CTD |
PMID:18204046 |
|
|
|
G |
Pcdha4 |
protocadherin alpha 4 |
affects methylation |
ISO |
Azacitidine affects the methylation of PCDHA4 promoter |
CTD |
PMID:18204046 |
|
NCBI chr18:28,581,040...28,846,214
Ensembl chr18:28,581,225...28,846,211
|
|
G |
Pcdha5 |
protocadherin alpha 5 |
affects methylation |
ISO |
Azacitidine affects the methylation of PCDHA5 promoter |
CTD |
PMID:18204046 |
|
|
|
G |
Pcdha6 |
protocadherin alpha 6 |
affects methylation |
ISO |
Azacitidine affects the methylation of PCDHA6 promoter |
CTD |
PMID:18204046 |
|
Ensembl chr18:28,581,225...28,846,211
|
|
G |
Pcdha7 |
protocadherin alpha 7 |
affects methylation |
ISO |
Azacitidine affects the methylation of PCDHA7 promoter |
CTD |
PMID:18204046 |
|
|
|
G |
Pcdha9 |
protocadherin alpha 9 |
affects methylation |
ISO |
Azacitidine affects the methylation of PCDHA8 promoter; Azacitidine affects the methylation of PCDHA9 promoter |
CTD |
PMID:18204046 |
|
|
|
G |
Pcdhb20 |
protocadherin beta 20 |
decreases expression |
ISO |
Azacitidine results in decreased expression of PCDHB14 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr18:29,211,883...29,215,258
Ensembl chr18:29,211,883...29,215,258
|
|
G |
Pcdhb5 |
protocadherin beta 5 |
decreases expression |
ISO |
Azacitidine results in decreased expression of PCDHB4 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr18:29,024,315...29,032,183
Ensembl chr18:29,028,382...29,053,259
|
|
G |
Pcna |
proliferating cell nuclear antigen |
decreases expression multiple interactions |
EXP |
Azacitidine results in decreased expression of PCNA protein [Cisplatin co-treated with Azacitidine] results in decreased expression of PCNA protein |
CTD |
PMID:19723570 |
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Pdk1 |
pyruvate dehydrogenase kinase 1 |
increases expression |
ISO |
Azacitidine results in increased expression of PDK1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 3:56,705,824...56,733,040
Ensembl chr 3:56,705,871...56,733,038
|
|
G |
Pdk4 |
pyruvate dehydrogenase kinase 4 |
increases expression decreases methylation |
ISO |
Azacitidine results in increased expression of PDK4 protein Azacitidine results in decreased methylation of PDK4 promoter |
CTD |
PMID:28003426 |
|
NCBI chr 4:33,591,796...33,601,798
Ensembl chr 4:33,589,799...33,601,850
|
|
G |
Pecam1 |
platelet and endothelial cell adhesion molecule 1 |
increases expression |
EXP |
Azacitidine results in increased expression of PECAM1 mRNA |
CTD |
PMID:18037191 |
|
NCBI chr10:91,590,521...91,652,279
Ensembl chr10:91,590,521...91,652,116
|
|
G |
Pfn1 |
profilin 1 |
increases expression |
ISO |
Azacitidine results in increased expression of PFN1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr10:55,365,263...55,367,968
Ensembl chr10:55,365,262...55,527,631
|
|
G |
Phactr2 |
phosphatase and actin regulator 2 |
increases expression |
ISO |
Azacitidine results in increased expression of PHACTR2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 1:7,591,254...7,860,431
Ensembl chr 1:7,597,927...7,860,289
|
|
G |
Pip5k1a |
phosphatidylinositol-4-phosphate 5-kinase, type 1, alpha |
decreases expression |
ISO |
Azacitidine results in decreased expression of PIP5K1A mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 2:182,628,299...182,671,584
Ensembl chr 2:182,628,300...182,671,598
|
|
G |
Pitpnc1 |
phosphatidylinositol transfer protein, cytoplasmic 1 |
decreases expression |
ISO |
Azacitidine results in decreased expression of PITPNC1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr10:92,163,558...92,428,971
Ensembl chr10:92,167,196...92,429,297
|
|
G |
Pitx3 |
paired-like homeodomain 3 |
increases expression |
EXP |
Azacitidine results in increased expression of PITX3 mRNA |
CTD |
PMID:27415467 |
|
NCBI chr 1:245,001,106...245,013,881
Ensembl chr 1:245,001,164...245,013,892
|
|
G |
Pja1 |
praja ring finger ubiquitin ligase 1 |
increases expression |
ISO |
Azacitidine results in increased expression of PJA1 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr X:64,580,938...64,585,864
Ensembl chr X:64,580,849...64,585,833
|
|
G |
Pkd2l1 |
polycystin 2 like 1, transient receptor potential cation channel |
increases expression |
ISO |
Azacitidine results in increased expression of PKD2L1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 1:243,032,853...243,070,031
Ensembl chr 1:243,032,913...243,070,031
|
|
G |
Pkm |
pyruvate kinase M1/2 |
increases expression |
ISO |
Azacitidine results in increased expression of PKM mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 8:60,057,629...60,079,600
Ensembl chr 8:60,057,402...60,079,599
|
|
G |
Plcb1 |
phospholipase C beta 1 |
decreases methylation decreases response to substance increases response to substance increases expression |
ISO |
Azacitidine results in decreased methylation of PLCB1 promoter PLCB1 promoter modified form results in decreased susceptibility to Azacitidine PLCB1 mRNA results in increased susceptibility to Azacitidine; PLCB1 protein results in increased susceptibility to Azacitidine Azacitidine results in increased expression of PLCB1 mRNA; Azacitidine results in increased expression of PLCB1 protein |
CTD |
PMID:19805378 |
|
NCBI chr 3:122,059,968...122,772,896
Ensembl chr 3:122,060,031...122,772,869
|
|
G |
Plpp1 |
phospholipid phosphatase 1 |
increases expression |
ISO |
Azacitidine results in increased expression of PLPP1 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 2:44,439,002...44,500,430
Ensembl chr 2:44,438,994...44,501,268
|
|
G |
Pls3 |
plastin 3 |
decreases expression |
ISO |
Azacitidine results in decreased expression of PLS3 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr X:111,589,193...111,683,908
Ensembl chr X:111,589,254...111,683,891
|
|
G |
Pml |
PML nuclear body scaffold |
increases expression |
ISO |
Azacitidine results in increased expression of PML mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 8:58,627,347...58,661,927
Ensembl chr 8:58,628,837...58,658,971
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
decreases methylation increases expression |
ISO |
Azacitidine results in decreased methylation of PPARG promoter Azacitidine results in increased expression of PPARG mRNA |
CTD |
PMID:19589179 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppp2ca |
protein phosphatase 2 catalytic subunit alpha |
multiple interactions increases expression decreases methylation |
ISO |
Azacitidine promotes the reaction [CREB1 protein modified form binds to PPP2CA promoter] Azacitidine results in increased expression of PPP2CA mRNA Azacitidine results in decreased methylation of PPP2CA promoter |
CTD |
PMID:19155497 |
|
NCBI chr10:36,358,110...36,377,864
Ensembl chr10:36,358,101...36,377,862
|
|
G |
Prdx4 |
peroxiredoxin 4 |
decreases expression |
EXP |
Azacitidine results in decreased expression of PRDX4 protein |
CTD |
PMID:17105402 |
|
NCBI chr X:40,026,762...40,044,066
Ensembl chr X:40,026,651...40,044,066
|
|
G |
Prf1 |
perforin 1 |
multiple interactions |
ISO |
Azacitidine inhibits the reaction [IL2 protein results in increased secretion of PRF1 protein] |
CTD |
PMID:19394699 |
|
NCBI chr20:29,246,202...29,251,712
Ensembl chr20:29,246,202...29,251,701
|
|
G |
Prl |
prolactin |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate co-treated with Azacitidine] results in increased expression of PRL mRNA; [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate co-treated with Azacitidine] results in increased expression of PRL protein |
CTD |
PMID:20823114 |
|
NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062
|
|
G |
Prom1 |
prominin 1 |
increases expression |
EXP |
Azacitidine results in increased expression of PROM1 mRNA |
CTD |
PMID:18037191 |
|
NCBI chr14:66,989,545...67,094,534
Ensembl chr14:66,990,160...67,094,527
|
|
G |
Prss12 |
serine protease 12 |
decreases expression |
ISO |
Azacitidine results in decreased expression of PRSS12 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:211,624,134...211,684,126
Ensembl chr 2:211,624,134...211,684,126
|
|
G |
Psen1 |
presenilin 1 |
decreases methylation multiple interactions |
ISO |
Azacitidine results in decreased methylation of PSEN1 promoter Betaine inhibits the reaction [Azacitidine results in decreased methylation of PSEN1 promoter] |
CTD |
PMID:19635394 |
|
NCBI chr 6:103,323,014...103,375,088
Ensembl chr 6:103,323,120...103,371,650
|
|
G |
Pten |
phosphatase and tensin homolog |
multiple interactions |
ISO |
Azacitidine inhibits the reaction [TGFB1 protein results in decreased expression of PTEN mRNA]; Azacitidine inhibits the reaction [TGFB1 protein results in decreased expression of PTEN protein]; Azacitidine inhibits the reaction [TGFB1 protein results in increased methylation of PTEN promoter] |
CTD |
PMID:22841775 |
|
NCBI chr 1:230,631,303...230,696,754
Ensembl chr 1:230,630,338...230,696,838
|
|
G |
Pthlh |
parathyroid hormone-like hormone |
decreases expression |
ISO |
Azacitidine results in decreased expression of PTHLH mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:180,188,792...180,199,847
Ensembl chr 4:180,188,792...180,199,847
|
|
G |
Ptpa |
protein phosphatase 2 phosphatase activator |
increases expression |
ISO |
Azacitidine results in increased expression of PTPA mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 3:13,689,742...13,720,287
Ensembl chr 3:13,689,741...13,722,549
|
|
G |
Ptprc |
protein tyrosine phosphatase, receptor type, C |
increases expression |
ISO |
Azacitidine results in increased expression of PTPRC mRNA |
CTD |
PMID:19194470 |
|
NCBI chr13:49,596,193...49,708,283
Ensembl chr13:49,596,193...49,708,692
|
|
G |
Ptpro |
protein tyrosine phosphatase, receptor type, O |
increases expression |
EXP |
Azacitidine results in increased expression of PTPRO mRNA |
CTD |
PMID:14508512 |
|
NCBI chr 4:170,164,071...170,374,790
Ensembl chr 4:170,164,431...170,374,771
|
|
G |
Rab13 |
RAB13, member RAS oncogene family |
decreases methylation |
ISO |
Azacitidine results in decreased methylation of RAB13 promoter |
CTD |
PMID:19194470 |
|
NCBI chr 2:175,674,894...175,680,043
Ensembl chr 2:175,675,005...175,680,036
|
|
G |
Rab1b |
RAB1B, member RAS oncogene family |
increases expression |
ISO |
Azacitidine results in increased expression of RAB1B mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 1:202,405,759...202,413,850
Ensembl chr 1:202,405,759...202,413,868
|
|
G |
Racgap1 |
Rac GTPase-activating protein 1 |
increases expression |
ISO |
Azacitidine results in increased expression of RACGAP1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 7:130,750,936...130,780,891
Ensembl chr 7:130,750,936...130,780,831
|
|
G |
Ranbp2 |
RAN binding protein 2 |
increases expression |
ISO |
Azacitidine results in increased expression of RANBP2 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr20:26,442,156...26,493,481
Ensembl chr20:26,442,217...26,493,481
|
|
G |
Rasa3 |
RAS p21 protein activator 3 |
increases expression |
ISO |
Azacitidine results in increased expression of RASA3 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr16:75,855,360...75,969,349
Ensembl chr16:75,855,265...75,970,804
|
|
G |
Rcn1 |
reticulocalbin 1 |
decreases expression |
ISO |
Azacitidine results in decreased expression of RCN1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 3:91,841,052...91,855,295
Ensembl chr 3:91,841,052...91,855,295
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
affects localization |
ISO |
Azacitidine affects the localization of RELA protein |
CTD |
PMID:18443271 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Ret |
ret proto-oncogene |
decreases expression |
ISO |
Azacitidine results in decreased expression of RET mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:151,325,969...151,368,176
Ensembl chr 4:151,326,431...151,368,176
|
|
G |
Rfc3 |
replication factor C subunit 3 |
multiple interactions |
ISO |
[Azacitidine co-treated with Thalidomide] affects the expression of RFC3 mRNA |
CTD |
PMID:18720364 |
|
NCBI chr12:1,000,987...1,011,778
Ensembl chr12:1,000,994...1,011,778
|
|
G |
Rhob |
ras homolog family member B |
multiple interactions |
ISO |
[trichostatin A co-treated with Azacitidine] results in increased expression of RHOB protein; Azacitidine promotes the reaction [trichostatin A results in increased expression of RHOB mRNA] |
CTD |
PMID:18047684 |
|
NCBI chr 6:31,363,752...31,365,926
Ensembl chr 6:31,363,548...31,366,108
|
|
G |
Rin1 |
Ras and Rab interactor 1 |
increases expression |
ISO |
Azacitidine results in increased expression of RIN1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 1:202,355,729...202,362,731
Ensembl chr 1:202,355,890...202,362,729
|
|
G |
Rpp21 |
ribonuclease P/MRP subunit p21 |
increases expression |
ISO |
Azacitidine results in increased expression of RPP21 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr20:2,018,170...2,020,100
Ensembl chr20:2,018,147...2,020,106
|
|
G |
Rps6 |
ribosomal protein S6 |
decreases phosphorylation |
ISO |
Azacitidine results in decreased phosphorylation of RPS6 protein |
CTD |
PMID:21245298 |
|
NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602 Ensembl chr 5:101,371,136...101,374,602
|
|
G |
Rpsa |
ribosomal protein SA |
decreases expression |
ISO |
Azacitidine results in decreased expression of RPSA mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 8:119,851,225...119,855,103
Ensembl chr 8:119,851,225...119,855,247
|
|
G |
Rrm2 |
ribonucleotide reductase regulatory subunit M2 |
multiple interactions |
ISO |
[Azacitidine co-treated with Thalidomide] affects the expression of RRM2 mRNA |
CTD |
PMID:18720364 |
|
NCBI chr 6:41,339,858...41,346,774
Ensembl chr 6:41,340,557...41,346,773
|
|
G |
Rrm2b |
ribonucleotide reductase regulatory TP53 inducible subunit M2B |
increases expression |
ISO |
Azacitidine results in increased expression of RRM2B mRNA |
CTD |
PMID:19010910 |
|
NCBI chr 7:69,077,024...69,108,742
Ensembl chr 7:69,078,291...69,108,633
|
|
G |
RT1-Da |
RT1 class II, locus Da |
multiple interactions |
ISO |
[Azacitidine promotes the reaction [IFNG protein results in increased expression of CIITA mRNA]] which results in increased expression of HLA-DRA protein |
CTD |
PMID:18829986 |
|
NCBI chr20:4,513,464...4,518,457
Ensembl chr20:4,512,911...4,518,455
|
|
G |
Runx1 |
RUNX family transcription factor 1 |
multiple interactions |
ISO |
Azacitidine promotes the reaction [RUNX1 protein binds to KIR2DL2 promoter]; Azacitidine promotes the reaction [RUNX1 protein binds to KIR2DL4 promoter] |
CTD |
PMID:18945643 |
|
NCBI chr11:31,839,880...32,074,427
Ensembl chr11:31,843,764...32,074,542
|
|
G |
Runx3 |
RUNX family transcription factor 3 |
affects methylation |
ISO |
Azacitidine affects the methylation of RUNX3 gene |
CTD |
PMID:18058463 |
|
NCBI chr 5:147,393,926...147,419,161
Ensembl chr 5:147,360,994...147,419,156
|
|
G |
S100a14 |
S100 calcium binding protein A14 |
decreases expression |
ISO |
Azacitidine results in decreased expression of S100A14 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:176,008,395...176,010,423
Ensembl chr 2:176,008,395...176,010,423
|
|
G |
S100a9 |
S100 calcium binding protein A9 |
increases expression |
ISO |
Azacitidine results in increased expression of S100A9 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 2:176,190,361...176,193,182
Ensembl chr 2:176,190,361...176,193,230
|
|
G |
Sall4 |
spalt-like transcription factor 4 |
affects methylation |
ISO |
Azacitidine affects the methylation of SALL4 promoter |
CTD |
PMID:17546590 |
|
NCBI chr 3:157,474,067...157,491,055
Ensembl chr 3:157,474,642...157,490,822
|
|
G |
Scamp4 |
secretory carrier membrane protein 4 |
increases expression |
ISO |
Azacitidine results in increased expression of SCAMP4 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 7:9,101,504...9,113,929
Ensembl chr 7:9,101,489...9,113,967
|
|
G |
Sdcbp |
syndecan binding protein |
decreases expression |
ISO |
Azacitidine results in decreased expression of SDCBP mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 5:19,473,499...19,517,188
Ensembl chr 5:19,489,961...19,527,572
|
|
G |
Sema3a |
semaphorin 3A |
increases expression |
ISO |
Azacitidine results in increased expression of SEMA3A mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:21,282,398...21,754,834
Ensembl chr 4:21,287,982...21,494,432
|
|
G |
Sema6c |
semaphorin 6C |
increases expression |
ISO |
Azacitidine results in increased expression of SEMA6C mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:182,733,635...182,750,066
Ensembl chr 2:182,737,474...182,746,856
|
|
G |
Senp3 |
SUMO specific peptidase 3 |
increases expression |
ISO |
Azacitidine results in increased expression of SENP3 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr10:54,390,698...54,399,590
Ensembl chr10:54,390,694...54,399,593
|
|
G |
Slbp |
stem-loop binding protein |
multiple interactions |
ISO |
Azacitidine inhibits the reaction [sodium arsenite results in decreased expression of SLBP mRNA] |
CTD |
PMID:25266719 |
|
NCBI chr14:77,071,441...77,081,911
Ensembl chr14:77,071,632...77,081,906
|
|
G |
Slc28a1 |
solute carrier family 28 member 1 |
increases response to substance multiple interactions increases uptake |
ISO |
SLC28A1 protein results in increased susceptibility to Azacitidine [SLC28A1 protein results in increased uptake of Azacitidine] which results in decreased expression of DNMT1 protein; Sodium affects the reaction [SLC28A1 protein results in increased uptake of Azacitidine] |
CTD |
PMID:19139132 |
|
NCBI chr 1:135,079,375...135,122,791
Ensembl chr 1:135,081,385...135,122,464
|
|
G |
Slc29a2 |
solute carrier family 29 member 2 |
decreases expression |
ISO |
Azacitidine results in decreased expression of SLC29A2 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 1:202,327,641...202,335,185
Ensembl chr 1:202,327,354...202,335,171
|
|
G |
Slc5a5 |
solute carrier family 5 member 5 |
multiple interactions increases expression |
ISO |
[Azacitidine co-treated with Butyrates] affects the expression of SLC5A5 mRNA Azacitidine results in increased expression of SLC5A5 mRNA |
CTD |
PMID:16954431 PMID:17164311 |
|
NCBI chr16:18,546,709...18,556,698
Ensembl chr16:18,546,709...18,556,697
|
|
G |
Snu13 |
small nuclear ribonucleoprotein 13 |
increases expression |
ISO |
Azacitidine results in increased expression of SNU13 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 7:113,565,903...113,570,871
Ensembl chr 7:113,565,295...113,570,872
|
|
G |
Socs3 |
suppressor of cytokine signaling 3 |
affects expression |
ISO |
Azacitidine affects the expression of SOCS3 protein |
CTD |
PMID:18443271 |
|
NCBI chr10:103,193,909...103,197,322
Ensembl chr10:103,193,537...103,197,787
|
|
G |
Sox13 |
SRY-box transcription factor 13 |
decreases expression |
ISO |
Azacitidine results in decreased expression of SOX13 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr13:44,831,097...44,875,522
Ensembl chr13:44,831,085...44,875,762
|
|
G |
Sox2 |
SRY-box transcription factor 2 |
increases expression |
EXP |
Azacitidine results in increased expression of SOX2 mRNA |
CTD |
PMID:27415467 |
|
NCBI chr 2:117,536,929...117,539,338
Ensembl chr 2:117,536,929...117,539,338
|
|
G |
Sox8 |
SRY-box transcription factor 8 |
decreases expression |
ISO |
Azacitidine results in decreased expression of SOX8 mRNA |
CTD |
PMID:18033690 |
|
NCBI chr10:14,584,829...14,589,818
Ensembl chr10:14,584,829...14,589,818
|
|
G |
Sox9 |
SRY-box transcription factor 9 |
affects expression |
ISO |
Azacitidine affects the expression of SOX9 mRNA |
CTD |
PMID:18033690 |
|
NCBI chr10:97,806,485...97,811,994
Ensembl chr10:97,806,485...97,811,994
|
|
G |
Sp1 |
Sp1 transcription factor |
multiple interactions decreases expression |
ISO |
Azacitidine promotes the reaction [SP1 protein binds to KIR2DL2 promoter]; Azacitidine promotes the reaction [SP1 protein binds to KIR2DL4 promoter] Azacitidine results in decreased expression of SP1 mRNA Azacitidine promotes the reaction [SP1 protein binds to AQP5 promoter] |
CTD |
PMID:17198683 PMID:18945643 PMID:20823114 |
|
NCBI chr 7:133,541,302...133,571,961
Ensembl chr 7:133,541,491...133,571,961
|
|
G |
Sp7 |
Sp7 transcription factor |
increases expression |
ISO |
Azacitidine results in increased expression of SP7 mRNA |
CTD |
PMID:17085970 |
|
NCBI chr 7:133,484,609...133,494,788
Ensembl chr 7:133,484,609...133,494,847
|
|
G |
Spag5 |
sperm associated antigen 5 |
multiple interactions |
ISO |
[Azacitidine co-treated with Thalidomide] affects the expression of SPAG5 mRNA |
CTD |
PMID:18720364 |
|
NCBI chr10:63,198,717...63,216,746
Ensembl chr10:63,198,768...63,216,745
|
|
G |
Srpx |
sushi-repeat-containing protein, X-linked |
decreases expression |
ISO |
Azacitidine results in decreased expression of SRPX mRNA |
CTD |
PMID:19194470 |
|
NCBI chr X:12,676,984...12,751,296
Ensembl chr X:12,566,645...12,747,882
|
|
G |
Srsf7 |
serine and arginine rich splicing factor 7 |
decreases expression |
ISO |
Azacitidine results in decreased expression of SRSF7 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 6:14,811,775...14,818,968
Ensembl chr 6:14,811,808...14,818,965
|
|
G |
Ssx2ip |
SSX family member 2 interacting protein |
increases expression |
ISO |
Azacitidine results in increased expression of SSX2IP mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:235,298,012...235,330,750
Ensembl chr 2:235,298,088...235,330,745
|
|
G |
St3gal6 |
ST3 beta-galactoside alpha-2,3-sialyltransferase 6 |
increases expression |
ISO |
Azacitidine results in increased expression of ST3GAL6 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr11:42,061,282...42,121,801
Ensembl chr11:42,077,621...42,121,776
|
|
G |
St8sia2 |
ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 2 |
decreases expression |
ISO |
Azacitidine results in decreased expression of ST8SIA2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 1:127,766,669...127,838,017
Ensembl chr 1:127,762,573...127,838,091
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
ISO |
[Azacitidine affects the expression of IL6R protein] which affects the phosphorylation of STAT3 protein |
CTD |
PMID:18443271 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Stc2 |
stanniocalcin 2 |
decreases expression |
ISO |
Azacitidine results in decreased expression of STC2 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr10:16,251,046...16,260,815
Ensembl chr10:16,250,853...16,262,973
|
|
G |
Stk38 |
serine/threonine kinase 38 |
decreases expression |
ISO |
Azacitidine results in decreased expression of STK38 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr20:7,034,245...7,067,803
Ensembl chr20:7,034,242...7,068,198
|
|
G |
Sulf1 |
sulfatase 1 |
decreases expression |
ISO |
Azacitidine results in decreased expression of SULF1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 5:6,362,896...6,526,174
Ensembl chr 5:6,362,911...6,525,584
|
|
G |
Sult1c2a |
sulfotransferase family, cytosolic, 1C, member 2a |
increases expression |
ISO |
Azacitidine results in increased expression of SULT1C2 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 9:6,873,697...6,904,736
Ensembl chr 9:6,874,249...6,904,734
|
|
G |
Tat |
tyrosine aminotransferase |
increases expression |
ISO |
Azacitidine results in increased expression of TAT mRNA |
CTD |
PMID:27590069 |
|
NCBI chr19:37,947,153...37,957,717
Ensembl chr19:37,947,112...37,958,031
|
|
G |
Tbc1d4 |
TBC1 domain family, member 4 |
decreases expression |
ISO |
Azacitidine results in decreased expression of TBC1D4 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr15:78,256,030...78,434,168
Ensembl chr15:78,257,121...78,434,265
|
|
G |
Tcea1 |
transcription elongation factor A1 |
decreases expression |
ISO |
Azacitidine results in decreased expression of TCEA1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 5:14,631,454...14,668,769
Ensembl chr 5:14,631,454...14,668,745
|
|
G |
Tecpr2 |
tectonin beta-propeller repeat containing 2 |
increases expression |
ISO |
Azacitidine results in increased expression of TECPR2 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 6:129,899,541...130,001,975
Ensembl chr 6:129,899,636...130,001,974
|
|
G |
Tek |
TEK receptor tyrosine kinase |
increases expression |
EXP |
Azacitidine results in increased expression of TEK mRNA |
CTD |
PMID:18037191 |
|
NCBI chr 5:109,607,077...109,733,805
Ensembl chr 5:109,607,077...109,733,804
|
|
G |
Tert |
telomerase reverse transcriptase |
decreases expression multiple interactions decreases methylation decreases activity |
ISO |
Azacitidine analog results in decreased expression of TERT mRNA; Azacitidine results in decreased expression of TERT mRNA E2F1 protein affects the reaction [Azacitidine results in decreased activity of TERT protein]; E2F1 protein affects the reaction [Azacitidine results in decreased expression of TERT mRNA]; MYC protein affects the reaction [Azacitidine results in decreased activity of TERT protein]; MYC protein affects the reaction [Azacitidine results in decreased expression of TERT mRNA] Azacitidine results in decreased methylation of TERT promoter |
CTD |
PMID:18045574 PMID:19451745 |
|
NCBI chr 1:29,637,213...29,659,509
Ensembl chr 1:29,637,506...29,659,561
|
|
G |
Tfe3 |
transcription factor binding to IGHM enhancer 3 |
increases expression |
ISO |
Azacitidine results in increased expression of TFE3 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr X:14,729,547...14,742,830
Ensembl chr X:14,729,550...14,742,571
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
[Azacitidine co-treated with TGFB1 protein] results in increased expression of FOXP3 protein Azacitidine inhibits the reaction [TGFB1 protein results in decreased expression of PTEN mRNA]; Azacitidine inhibits the reaction [TGFB1 protein results in decreased expression of PTEN protein]; Azacitidine inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA]; Azacitidine inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA]; Azacitidine inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 protein]; Azacitidine inhibits the reaction [TGFB1 protein results in increased methylation of PTEN promoter]; Azacitidine inhibits the reaction [TGFB1 protein results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:18493985 PMID:22841775 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Thumpd1 |
THUMP domain containing 1 |
increases expression |
ISO |
Azacitidine results in increased expression of THUMPD1 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 1:174,078,875...174,084,915
Ensembl chr 1:174,078,878...174,084,937
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
increases expression |
ISO |
Azacitidine results in increased expression of TIMP1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Tjp1 |
tight junction protein 1 |
increases expression |
ISO |
Azacitidine results in increased expression of TJP1 mRNA |
CTD |
PMID:18661270 |
|
NCBI chr 1:118,849,838...119,094,492
Ensembl chr 1:118,849,838...119,094,432
|
|
G |
Tmed3 |
transmembrane p24 trafficking protein 3 |
increases expression |
ISO |
Azacitidine results in increased expression of TMED3 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 8:90,241,516...90,249,429
Ensembl chr 8:90,241,516...90,249,346
|
|
G |
Tmpo |
thymopoietin |
multiple interactions |
ISO |
[Azacitidine co-treated with Thalidomide] affects the expression of TMPO mRNA |
CTD |
PMID:18720364 |
|
NCBI chr 7:25,642,752...25,667,756
Ensembl chr 7:25,586,725...25,667,727
|
|
G |
Tnc |
tenascin C |
decreases expression |
ISO |
Azacitidine results in decreased expression of TNC mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 5:77,375,851...77,460,712
Ensembl chr 5:77,375,851...77,460,624
|
|
G |
Tnf |
tumor necrosis factor |
increases expression increases response to substance |
EXP ISO |
Azacitidine results in increased expression of TNF mRNA Azacitidine results in increased susceptibility to TNF protein |
CTD |
PMID:17156202 PMID:18829727 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfsf10 |
TNF superfamily member 10 |
increases response to substance |
ISO |
Azacitidine results in increased susceptibility to TNFSF10 protein |
CTD |
PMID:18829727 |
|
NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135
|
|
G |
Tnni3 |
troponin I3, cardiac type |
increases expression |
EXP |
Azacitidine results in increased expression of TNNI3 protein |
CTD |
PMID:17105402 |
|
NCBI chr 1:69,299,900...69,303,582
Ensembl chr 1:69,299,900...69,303,580
|
|
G |
Tnnt2 |
troponin T2, cardiac type |
increases expression |
EXP |
Azacitidine results in increased expression of TNNT2 protein |
CTD |
PMID:22496879 |
|
NCBI chr13:47,267,325...47,285,390
Ensembl chr13:47,267,204...47,285,388
|
|
G |
Top2a |
DNA topoisomerase II alpha |
multiple interactions |
ISO |
[Azacitidine co-treated with Thalidomide] affects the expression of TOP2A mRNA; [Curcumin co-treated with Azacitidine] results in decreased expression of TOP2A mRNA |
CTD |
PMID:18348204 PMID:18720364 |
|
NCBI chr10:83,946,186...83,975,694
Ensembl chr10:83,945,735...83,976,874
|
|
G |
Tp73 |
tumor protein p73 |
multiple interactions |
ISO |
TP73 protein promotes the reaction [Azacitidine results in increased expression of HMGA2 mRNA]; TP73 protein promotes the reaction [Azacitidine results in increased expression of KLF6 mRNA]; TP73 protein promotes the reaction [Azacitidine results in increased expression of NIBAN1 mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr 5:164,621,377...164,703,958
Ensembl chr 5:164,621,377...164,681,128
|
|
G |
Tpd52 |
tumor protein D52 |
increases expression |
EXP |
Azacitidine results in increased expression of TPD52 mRNA |
CTD |
PMID:27415467 |
|
NCBI chr 2:92,735,246...92,816,079
Ensembl chr 2:92,735,620...92,816,622
|
|
G |
Tpm2 |
tropomyosin 2 |
increases expression |
ISO |
Azacitidine results in increased expression of TPM2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 5:57,770,919...57,780,278
Ensembl chr 5:57,770,864...57,779,992
|
|
G |
Tpo |
thyroid peroxidase |
increases expression |
ISO |
Azacitidine results in increased expression of TPO mRNA |
CTD |
PMID:17679169 |
|
NCBI chr 6:46,698,402...46,768,199
Ensembl chr 6:46,698,414...46,768,199
|
|
G |
Tpsg1 |
tryptase gamma 1 |
decreases expression |
ISO |
Azacitidine results in decreased expression of TPSG1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr10:14,386,352...14,390,258
Ensembl chr10:14,386,352...14,390,258
|
|
G |
Trh |
thyrotropin releasing hormone |
decreases expression |
ISO |
Azacitidine results in decreased expression of TRH mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 4:124,742,111...124,777,094
Ensembl chr 4:124,742,111...124,744,637
|
|
G |
Trib1 |
tribbles pseudokinase 1 |
decreases expression |
ISO |
Azacitidine results in decreased expression of TRIB1 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 7:91,206,579...91,213,126
Ensembl chr 7:91,206,579...91,214,731
|
|
G |
Trim8 |
tripartite motif-containing 8 |
increases expression |
ISO |
Azacitidine results in increased expression of TRIM8 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 1:245,369,632...245,384,513
Ensembl chr 1:245,369,632...245,384,513
|
|
G |
Tsc1 |
TSC complex subunit 1 |
multiple interactions |
ISO |
[Azacitidine affects the methylation of TSC1 promoter] which affects the expression of TSC1 mRNA |
CTD |
PMID:18538015 |
|
NCBI chr 3:11,969,547...12,018,591
Ensembl chr 3:11,979,729...12,015,674
|
|
G |
Tsc2 |
TSC complex subunit 2 |
decreases methylation multiple interactions increases expression |
ISO |
Azacitidine results in decreased methylation of TSC2 promoter [Azacitidine affects the methylation of TSC2 promoter] which affects the expression of TSC2 mRNA Azacitidine results in increased expression of TSC2 mRNA |
CTD |
PMID:18538015 PMID:19250671 |
|
NCBI chr10:13,621,135...13,655,773
Ensembl chr10:13,621,136...13,655,951
|
|
G |
Tshr |
thyroid stimulating hormone receptor |
increases expression |
ISO |
Azacitidine results in increased expression of TSHR mRNA |
CTD |
PMID:17679169 |
|
NCBI chr 6:110,341,585...110,475,297
Ensembl chr 6:110,341,581...110,474,538
|
|
G |
Tspan32 |
tetraspanin 32 |
decreases expression |
ISO |
Azacitidine results in decreased expression of TSPAN32 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 1:198,190,128...198,204,447
Ensembl chr 1:198,190,164...198,204,445
|
|
G |
Ttk |
Ttk protein kinase |
multiple interactions |
ISO |
[Azacitidine co-treated with Thalidomide] affects the expression of TTK mRNA |
CTD |
PMID:18720364 |
|
NCBI chr 8:84,754,329...84,792,653
Ensembl chr 8:84,754,315...84,792,651
|
|
G |
Ube2c |
ubiquitin-conjugating enzyme E2C |
multiple interactions |
ISO |
[Azacitidine co-treated with Thalidomide] affects the expression of UBE2C mRNA |
CTD |
PMID:18720364 |
|
NCBI chr 3:153,506,636...153,509,036
Ensembl chr 3:153,506,636...153,513,339
|
|
G |
Uhmk1 |
U2AF homology motif kinase 1 |
increases expression |
ISO |
Azacitidine results in increased expression of UHMK1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr13:82,396,646...82,416,292
Ensembl chr13:82,401,187...82,416,292
|
|
G |
Ush2a |
usherin |
increases expression |
ISO |
Azacitidine results in increased expression of USH2A mRNA |
CTD |
PMID:20823114 |
|
NCBI chr13:99,837,445...100,503,935
Ensembl chr13:99,837,445...100,503,922
|
|
G |
Ushbp1 |
USH1 protein network component harmonin binding protein 1 |
decreases expression |
ISO |
Azacitidine results in decreased expression of USHBP1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr16:18,057,321...18,067,933
Ensembl chr16:18,057,326...18,067,877
|
|
G |
Vim |
vimentin |
decreases expression increases expression multiple interactions |
EXP ISO |
Azacitidine results in decreased expression of VIM protein Azacitidine results in increased expression of VIM mRNA; Azacitidine results in increased expression of VIM protein [Azacitidine co-treated with Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of VIM protein |
CTD |
PMID:17105402 PMID:20823114 |
|
NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187
|
|
G |
Wdr47 |
WD repeat domain 47 |
decreases expression |
ISO |
Azacitidine results in decreased expression of WDR47 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 2:196,226,757...196,287,739
Ensembl chr 2:196,205,238...196,287,739
|
|
G |
Wnt10b |
Wnt family member 10B |
increases expression |
EXP |
Azacitidine results in increased expression of WNT10B mRNA |
CTD |
PMID:27415467 |
|
NCBI chr 7:129,922,088...129,927,892
Ensembl chr 7:129,922,088...129,927,892
|
|
G |
Wnt5a |
Wnt family member 5A |
increases expression |
ISO |
Azacitidine results in increased expression of WNT5A mRNA |
CTD |
PMID:20823114 |
|
NCBI chr16:3,695,667...3,718,234
Ensembl chr16:3,697,032...3,718,234
|
|
G |
Wwtr1 |
WW domain containing transcription regulator 1 |
increases expression |
ISO |
Azacitidine results in increased expression of WWTR1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:141,651,159...141,766,919
Ensembl chr 2:141,648,108...141,766,968
|
|
G |
Xaf1 |
XIAP associated factor 1 |
decreases expression decreases methylation increases expression |
ISO |
Azacitidine results in decreased expression of XAF1 mRNA alternative form Azacitidine results in decreased methylation of XAF1 promoter Azacitidine results in increased expression of XAF1 mRNA; Azacitidine results in increased expression of XAF1 protein |
CTD |
PMID:19077051 PMID:19549372 |
|
NCBI chr10:56,917,284...56,929,791
Ensembl chr10:56,917,121...56,929,770
|
|
G |
Zfp189 |
zinc finger protein 189 |
decreases expression |
ISO |
Azacitidine results in decreased expression of ZNF189 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 5:63,872,596...63,884,348
Ensembl chr 5:63,872,738...63,884,121
|
|
G |
Zfp64 |
zinc finger protein 64 |
affects methylation |
ISO |
Azacitidine affects the methylation of ZFP64 promoter |
CTD |
PMID:17546590 |
|
NCBI chr 3:157,666,819...157,695,774
Ensembl chr 3:157,633,211...157,695,809
|
|
G |
Zp3 |
zona pellucida glycoprotein 3 |
increases expression |
ISO |
Azacitidine results in increased expression of ZP3 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr12:20,690,547...20,697,513
Ensembl chr12:20,690,547...20,697,513
|
|
|
G |
Gcg |
glucagon |
multiple interactions |
ISO |
9-(tetrahydro-2-furyl)-adenine inhibits the reaction [geraniol results in increased secretion of GCG protein] |
CTD |
PMID:29070885 |
|
NCBI chr 3:47,113,914...47,122,929
Ensembl chr 3:47,113,914...47,122,929
|
|
G |
Pnpla6 |
patatin-like phospholipase domain containing 6 |
decreases expression |
ISO |
9-(tetrahydro-2-furyl)-adenine results in decreased expression of PNPLA6 mRNA; 9-(tetrahydro-2-furyl)-adenine results in decreased expression of PNPLA6 protein |
CTD |
PMID:20380879 |
|
NCBI chr12:1,574,387...1,603,735
Ensembl chr12:1,560,363...1,603,734
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
9-(tetrahydro-2-furyl)-adenine inhibits the reaction [methylmercuric chloride results in increased expression of PTGS2 protein] |
CTD |
PMID:28958600 |
|
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
decreases expression multiple interactions |
EXP ISO |
acadesine decreases expression of Abcb11 mRNA in primary hepatocytes acadesine inhibits the reaction [picroside II inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of ABCB11 mRNA]]; acadesine inhibits the reaction [picroside II inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of ABCB11 protein]] |
CTD RGD |
PMID:32976922 PMID:27090119 |
RGD:15090804 |
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
decreases expression |
EXP |
acadesine decreases expression of Abcc2 mRNA in primary hepatocytes |
RGD |
PMID:27090119 |
RGD:15090804 |
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
increases phosphorylation |
EXP |
acadesine results in increased phosphorylation of ACACA protein |
CTD |
PMID:22496244 |
|
NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
|
|
G |
Acads |
acyl-CoA dehydrogenase short chain |
multiple interactions |
EXP |
acadesine inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of ACADS mRNA]; acadesine inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of and results in decreased activity of ACADS protein] |
CTD |
PMID:26989860 |
|
NCBI chr12:41,493,650...41,502,897
Ensembl chr12:41,493,626...41,502,898
|
|
G |
Agrp |
agouti related neuropeptide |
increases expression |
ISO |
acadesine results in increased expression of AGRP mRNA |
CTD |
PMID:32575098 |
|
NCBI chr19:33,447,992...33,523,068
Ensembl chr19:33,447,992...33,449,584
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
EXP |
acadesine inhibits the reaction [AGT protein results in decreased expression of GJA1 protein]; acadesine inhibits the reaction [AGT protein results in decreased expression of GJA5 protein]; dorsomorphin inhibits the reaction [acadesine inhibits the reaction [AGT protein results in decreased expression of GJA1 protein]] |
CTD |
PMID:33676887 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
increases phosphorylation decreases phosphorylation |
ISO |
acadesine results in increased phosphorylation of AKT1 protein acadesine results in decreased phosphorylation of AKT1 protein |
CTD |
PMID:22137261 PMID:25603053 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Apln |
apelin |
multiple interactions |
ISO |
acadesine inhibits the reaction [Thioctic Acid results in increased expression of APLN mRNA]; acadesine inhibits the reaction [Thioctic Acid results in increased secretion of APLN protein] |
CTD |
PMID:21461750 |
|
NCBI chr X:127,180,801...127,213,567
Ensembl chr X:127,203,823...127,213,391
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
EXP |
acadesine inhibits the reaction [tert-Butylhydroperoxide results in increased expression of BAX protein] |
CTD |
PMID:26989860 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
EXP ISO |
acadesine inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of BCL2 protein] acadesine promotes the reaction [Artesunate results in decreased expression of BCL2 protein] |
CTD |
PMID:26989860 PMID:33002460 |
|
NCBI chr13:22,689,783...22,853,920
|
|
G |
Becn1 |
beclin 1 |
multiple interactions |
ISO |
acadesine promotes the reaction [Zearalenone results in increased expression of BECN1 protein] |
CTD |
PMID:31982503 |
|
NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases cleavage |
ISO EXP |
acadesine promotes the reaction [Isoniazid results in increased cleavage of CASP3 protein] acadesine inhibits the reaction [tert-Butylhydroperoxide results in increased cleavage of CASP3 protein] acadesine results in increased cleavage of CASP3 protein |
CTD |
PMID:22137261 PMID:25603053 PMID:26989860 PMID:28556920 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
increases cleavage |
ISO |
acadesine results in increased cleavage of CASP9 protein |
CTD |
PMID:22137261 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
EXP |
acadesine inhibits the reaction [Acrylamide results in increased expression of CYP2E1 protein]; acadesine inhibits the reaction [glycidamide results in increased expression of CYP2E1 protein] |
CTD |
PMID:33545342 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp8b1 |
cytochrome P450 family 8 subfamily B member 1 |
multiple interactions |
ISO |
acadesine promotes the reaction [picroside II promotes the reaction [1-Naphthylisothiocyanate results in decreased expression of CYP8B1 mRNA]]; acadesine promotes the reaction [picroside II promotes the reaction [1-Naphthylisothiocyanate results in decreased expression of CYP8B1 protein]] |
CTD |
PMID:32976922 |
|
NCBI chr 8:121,578,123...121,580,093
Ensembl chr 8:121,557,062...121,580,166
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions |
ISO |
acadesine inhibits the reaction [Dibutyl Phthalate results in increased expression of FASN protein] |
CTD |
PMID:33508418 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
multiple interactions |
EXP |
acadesine inhibits the reaction [AGT protein results in decreased expression of GJA1 protein]; dorsomorphin inhibits the reaction [acadesine inhibits the reaction [AGT protein results in decreased expression of GJA1 protein]] |
CTD |
PMID:33676887 |
|
NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582
|
|
G |
Gja5 |
gap junction protein, alpha 5 |
multiple interactions |
EXP |
acadesine inhibits the reaction [AGT protein results in decreased expression of GJA5 protein] |
CTD |
PMID:33676887 |
|
NCBI chr 2:184,602,407...184,621,952
Ensembl chr 2:184,564,475...184,621,952
|
|
G |
Gpam |
glycerol-3-phosphate acyltransferase, mitochondrial |
multiple interactions |
ISO |
acadesine inhibits the reaction [[Oleic Acid co-treated with Dibutyl Phthalate] results in increased expression of GPAM protein]; acadesine inhibits the reaction [Dibutyl Phthalate results in increased expression of GPAM protein] |
CTD |
PMID:33508418 |
|
NCBI chr 1:254,106,323...254,170,755
Ensembl chr 1:254,106,331...254,142,639
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
multiple interactions |
ISO |
acadesine promotes the reaction [Artesunate results in increased lipidation of MAP1LC3B protein] |
CTD |
PMID:33002460 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
EXP |
acadesine inhibits the reaction [Acrylamide results in increased phosphorylation of MAPK1 protein]; acadesine inhibits the reaction [glycidamide results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:33545342 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
EXP |
acadesine inhibits the reaction [Acrylamide results in increased phosphorylation of MAPK3 protein]; acadesine inhibits the reaction [glycidamide results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:33545342 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mef2c |
myocyte enhancer factor 2C |
decreases expression |
ISO |
acadesine results in decreased expression of MEF2C mRNA |
CTD |
PMID:15864539 |
|
NCBI chr 2:13,973,299...14,136,065
Ensembl chr 2:13,993,438...14,132,880
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
multiple interactions |
ISO |
acadesine promotes the reaction [Zearalenone results in decreased phosphorylation of MTOR protein] acadesine promotes the reaction [Artesunate results in decreased phosphorylation of MTOR protein] |
CTD |
PMID:31982503 PMID:33002460 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
decreases expression multiple interactions |
EXP ISO |
acadesine decreases expression of Nr1h4 mRNA and protein in primary hepatocytes acadesine inhibits the reaction [picroside II inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of NR1H4 mRNA]]; acadesine inhibits the reaction [picroside II inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of NR1H4 protein]] |
CTD RGD |
PMID:32976922 PMID:27090119 |
RGD:15090804 |
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Nrf1 |
nuclear respiratory factor 1 |
multiple interactions increases expression |
ISO |
acadesine inhibits the reaction [Isoniazid results in decreased expression of NRF1 protein] acadesine results in increased expression of NRF1 protein |
CTD |
PMID:28556920 |
|
NCBI chr 4:58,664,932...58,772,328
Ensembl chr 4:58,664,957...58,825,328
|
|
G |
Ocln |
occludin |
multiple interactions |
ISO |
acadesine promotes the reaction [1-Naphthylisothiocyanate results in decreased expression of OCLN protein] |
CTD |
PMID:33400020 |
|
NCBI chr 2:31,657,217...31,707,466
Ensembl chr 2:31,657,220...31,764,150
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
ISO |
acadesine promotes the reaction [Artesunate results in increased cleavage of PARP1 protein] |
CTD |
PMID:33002460 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
EXP |
acadesine inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of PPARA mRNA]; acadesine inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of PPARA protein] |
CTD |
PMID:26989860 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions increases expression |
ISO EXP |
acadesine inhibits the reaction [Isoniazid results in decreased expression of PPARGC1A protein] acadesine results in increased expression of PPARGC1A mRNA Dietary Fats promotes the reaction [acadesine results in increased expression of PPARGC1A mRNA] acadesine results in increased expression of PPARGC1A protein |
CTD |
PMID:22496244 PMID:28556920 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Prkaa1 |
protein kinase AMP-activated catalytic subunit alpha 1 |
increases phosphorylation |
EXP ISO |
acadesine increases phosphorylation of Prkaa1 in primary hepatocytes acadesine results in increased phosphorylation of PRKAA1 protein |
CTD RGD |
PMID:22815988 PMID:33676887 PMID:27090119 |
RGD:15090804 |
NCBI chr 2:54,240,298...54,275,978
Ensembl chr 2:54,240,137...54,275,978
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
acadesine inhibits the reaction [[Fluorouracil results in increased expression of PTGS2 protein] which results in increased abundance of and results in increased secretion of Dinoprostone]; acadesine inhibits the reaction [Fluorouracil results in increased expression of PTGS2 protein] |
CTD |
PMID:15896711 |
|
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
multiple interactions |
ISO |
acadesine promotes the reaction [Zearalenone results in decreased phosphorylation of RPS6KB1 protein] |
CTD |
PMID:31982503 |
|
NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions increases expression |
ISO |
acadesine inhibits the reaction [Isoniazid results in decreased expression of SIRT1 protein] acadesine results in increased expression of SIRT1 protein |
CTD |
PMID:28556920 |
|
NCBI chr20:25,307,143...25,329,260
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Slc10a1 |
solute carrier family 10 member 1 |
decreases expression |
EXP |
acadesine decreases expression of Slc10a1 mRNA in primary hepatocytes |
RGD |
PMID:27090119 |
RGD:15090804 |
NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670
|
|
G |
Slc2a1 |
solute carrier family 2 member 1 |
increases expression |
ISO |
acadesine results in increased expression of SLC2A1 mRNA |
CTD |
PMID:15864539 |
|
NCBI chr 5:132,717,196...132,745,416
Ensembl chr 5:132,717,196...132,745,416
|
|
G |
Slco1a4 |
solute carrier organic anion transporter family, member 1a4 |
decreases expression |
EXP |
acadesine decreases expression of Slco1a4 mRNA in primary hepatocytes |
RGD |
PMID:27090119 |
RGD:15090804 |
NCBI chr 4:174,710,004...174,764,810
Ensembl chr 4:174,710,004...175,254,573
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions |
ISO |
acadesine inhibits the reaction [Dibutyl Phthalate results in increased expression of SREBF1 protein] |
CTD |
PMID:33508418 |
|
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Tjp1 |
tight junction protein 1 |
multiple interactions |
ISO |
acadesine inhibits the reaction [SEW2871 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of TJP1 protein]]; acadesine promotes the reaction [1-Naphthylisothiocyanate results in decreased expression of TJP1 protein] |
CTD |
PMID:33400020 |
|
NCBI chr 1:118,849,838...119,094,492
Ensembl chr 1:118,849,838...119,094,432
|
|
G |
Ulk1 |
unc-51 like autophagy activating kinase 1 |
multiple interactions |
ISO |
acadesine promotes the reaction [Artesunate results in increased phosphorylation of ULK1 protein] |
CTD |
PMID:33002460 |
|
NCBI chr12:45,851,710...45,877,966
Ensembl chr12:45,851,710...45,877,966
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
decreases expression |
EXP |
AICA ribonucleotide results in decreased expression of ABCB11 mRNA |
CTD |
PMID:27090119 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
decreases expression |
EXP |
AICA ribonucleotide results in decreased expression of ABCC2 mRNA |
CTD |
PMID:27090119 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abl1 |
ABL proto-oncogene 1, non-receptor tyrosine kinase |
multiple interactions |
ISO |
AICA ribonucleotide promotes the reaction [ABL1 protein mutant form binds to BECN1 protein]; AICA ribonucleotide promotes the reaction [ABL1 protein mutant form binds to XPO1 protein]; AICA ribonucleotide promotes the reaction [ABL1 protein mutant form binds to YWHAQ protein]; AICA ribonucleotide results in decreased expression of and affects the localization of ABL1 protein mutant form |
CTD |
PMID:33070465 |
|
NCBI chr 3:14,979,853...15,083,065
Ensembl chr 3:14,979,853...15,083,065
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
increases phosphorylation multiple interactions increases expression |
ISO EXP |
AICA ribonucleotide results in increased phosphorylation of ACACA protein AICA ribonucleotide inhibits the reaction [fipronil results in increased expression of and results in decreased phosphorylation of ACACA protein]; AICA ribonucleotide results in decreased expression of and results in increased phosphorylation of ACACA protein AICA ribonucleotide results in increased expression of ACACA protein modified form |
CTD |
PMID:15297373 PMID:16020477 PMID:16873680 PMID:20080969 PMID:25743752 PMID:27103584 More...
|
|
NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
|
|
G |
Acacb |
acetyl-CoA carboxylase beta |
increases phosphorylation |
ISO |
AICA ribonucleotide results in increased phosphorylation of ACACB protein |
CTD |
PMID:16873680 |
|
NCBI chr12:42,365,800...42,477,651
Ensembl chr12:42,366,548...42,457,655
|
|
G |
Acadm |
acyl-CoA dehydrogenase medium chain |
multiple interactions increases expression |
EXP ISO |
AICA ribonucleotide inhibits the reaction [Phenylephrine results in decreased expression of ACADM mRNA] AICA ribonucleotide results in increased expression of ACADM mRNA; AICA ribonucleotide results in increased expression of ACADM protein |
CTD |
PMID:19699196 PMID:25743752 |
|
NCBI chr 2:242,858,865...242,883,036
Ensembl chr 2:242,858,865...242,883,147
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
ISO |
AICA ribonucleotide inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein] |
CTD |
PMID:27688165 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
increases expression multiple interactions |
ISO EXP |
AICA ribonucleotide results in increased expression of ADIPOQ protein AICA ribonucleotide inhibits the reaction [Palmitic Acid results in decreased expression of ADIPOQ mRNA] |
CTD |
PMID:20980258 PMID:25108154 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
AICA ribonucleotide inhibits the reaction [AKT1 protein mutant form results in decreased oxidation of Fatty Acids]; AICA ribonucleotide inhibits the reaction [AKT1 protein mutant form results in increased phosphorylation of EIF4EBP1 protein]; AICA ribonucleotide inhibits the reaction [AKT1 protein mutant form results in increased susceptibility to Glucose deficiency]; PRKAA2 protein affects the reaction [AICA ribonucleotide inhibits the reaction [AKT1 protein mutant form affects the susceptibility to Glucose deficiency]] |
CTD |
PMID:15806154 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
App |
amyloid beta precursor protein |
decreases expression |
ISO |
AICA ribonucleotide results in decreased expression of APP protein modified form |
CTD |
PMID:20080969 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Arg1 |
arginase 1 |
multiple interactions |
EXP |
AICA ribonucleotide inhibits the reaction [Palmitic Acid results in decreased expression of ARG1 mRNA] |
CTD |
PMID:25108154 |
|
NCBI chr 1:20,475,878...20,488,422
Ensembl chr 1:20,475,968...20,488,422
|
|
G |
Atg5 |
autophagy related 5 |
multiple interactions |
ISO |
AICA ribonucleotide inhibits the reaction [Ethanol results in decreased expression of ATG5 protein] |
CTD |
PMID:24582693 |
|
NCBI chr20:47,798,222...47,889,216
Ensembl chr20:47,798,290...47,889,209
|
|
G |
Becn1 |
beclin 1 |
increases expression multiple interactions |
EXP ISO |
AICA ribonucleotide results in increased expression of BECN1 protein AICA ribonucleotide promotes the reaction [ABL1 protein mutant form binds to BECN1 protein]; AICA ribonucleotide promotes the reaction [XPO1 protein binds to BECN1 protein]; AICA ribonucleotide results in increased expression of and affects the localization of BECN1 protein AICA ribonucleotide promotes the reaction [4-nonylphenol results in increased expression of BECN1 protein] |
CTD |
PMID:28041982 PMID:33070465 |
|
NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742
|
|
G |
Casp3 |
caspase 3 |
increases activity multiple interactions |
EXP ISO |
AICA ribonucleotide results in increased activity of CASP3 protein AICA ribonucleotide inhibits the reaction [sunitinib results in increased cleavage of CASP3 protein] |
CTD |
PMID:16469385 PMID:21906609 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp7 |
caspase 7 |
multiple interactions |
ISO |
AICA ribonucleotide inhibits the reaction [sunitinib results in increased cleavage of CASP7 protein] |
CTD |
PMID:21906609 |
|
NCBI chr 1:255,437,195...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp9 |
caspase 9 |
increases activity |
EXP |
AICA ribonucleotide results in increased activity of CASP9 protein |
CTD |
PMID:16469385 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions increases expression |
ISO |
AICA ribonucleotide promotes the reaction [FOXO1 protein results in increased expression of CAT mRNA] AICA ribonucleotide results in increased expression of CAT mRNA; AICA ribonucleotide results in increased expression of CAT protein |
CTD |
PMID:25065674 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions decreases expression |
EXP ISO |
AICA ribonucleotide inhibits the reaction [Palmitic Acid results in increased expression of CCL2 mRNA] AICA ribonucleotide results in decreased expression of CCL2 mRNA AICA ribonucleotide inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; dorsomorphin inhibits the reaction [AICA ribonucleotide inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]]; dorsomorphin inhibits the reaction [AICA ribonucleotide results in decreased expression of CCL2 mRNA] |
CTD |
PMID:24465016 PMID:25108154 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
multiple interactions |
ISO |
AICA ribonucleotide inhibits the reaction [Palmitic Acid results in increased expression of CCL3 mRNA] |
CTD |
PMID:21745629 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Ccna2 |
cyclin A2 |
multiple interactions decreases expression |
ISO |
AICA ribonucleotide inhibits the reaction [ELAVL1 protein binds to CCNA2 3' UTR] AICA ribonucleotide results in decreased expression of CCNA2 mRNA; AICA ribonucleotide results in decreased expression of CCNA2 protein |
CTD |
PMID:12730239 |
|
NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577
|
|
G |
Ccnb1 |
cyclin B1 |
multiple interactions decreases expression |
ISO |
AICA ribonucleotide inhibits the reaction [ELAVL1 protein binds to CCNB1 3' UTR] AICA ribonucleotide results in decreased expression of CCNB1 mRNA; AICA ribonucleotide results in decreased expression of CCNB1 protein |
CTD |
PMID:12730239 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Cd36 |
CD36 molecule |
multiple interactions |
ISO |
AICA ribonucleotide results in increased expression of and affects the localization of CD36 protein |
CTD |
PMID:28038998 |
|
NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
decreases expression multiple interactions |
ISO |
AICA ribonucleotide results in decreased expression of CEBPA protein AICA ribonucleotide inhibits the reaction [fipronil results in increased expression of CEBPA protein] |
CTD |
PMID:27103584 |
|
NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
increases phosphorylation |
ISO |
AICA ribonucleotide results in increased phosphorylation of CEBPB protein |
CTD |
PMID:28038998 |
|
NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473
|
|
G |
Cftr |
CF transmembrane conductance regulator |
multiple interactions |
EXP |
AICA ribonucleotide inhibits the reaction [Colforsin results in increased activity of CFTR protein] |
CTD |
PMID:12519745 |
|
NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions |
ISO |
AICA ribonucleotide inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 protein] |
CTD |
PMID:27688165 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
increases expression multiple interactions |
ISO |
AICA ribonucleotide results in increased expression of CPT1A mRNA; AICA ribonucleotide results in increased expression of CPT1A protein AICA ribonucleotide inhibits the reaction [TP53 gene mutant form results in increased expression of CPT1A protein] dorsomorphin inhibits the reaction [AICA ribonucleotide results in increased expression of CPT1A mRNA] |
CTD |
PMID:24465016 PMID:25743752 PMID:33070465 |
|
NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Cpt1b |
carnitine palmitoyltransferase 1B |
multiple interactions |
EXP |
AICA ribonucleotide inhibits the reaction [Phenylephrine results in decreased expression of CPT1B mRNA]; AICA ribonucleotide inhibits the reaction [Phenylephrine results in decreased expression of CPT1B protein] |
CTD |
PMID:19699196 |
|
NCBI chr 7:120,491,354...120,500,833
Ensembl chr 7:120,491,354...120,500,404
|
|
G |
Ctnnb1 |
catenin beta 1 |
multiple interactions increases expression |
ISO |
[AICA ribonucleotide results in increased phosphorylation of HDAC5 protein] which results in increased expression of CTNNB1 mRNA; [AICA ribonucleotide results in increased phosphorylation of HDAC5 protein] which results in increased expression of CTNNB1 protein; AICA ribonucleotide inhibits the reaction [[HDAC5 protein binds to MEF2 protein] which binds to CTNNB1 promoter]; PRKAA2 protein affects the reaction [AICA ribonucleotide results in increased expression of CTNNB1 mRNA]; PRKAA2 protein affects the reaction [AICA ribonucleotide results in increased expression of CTNNB1 protein] AICA ribonucleotide results in increased expression of CTNNB1 mRNA; AICA ribonucleotide results in increased expression of CTNNB1 protein |
CTD |
PMID:21454484 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Cyba |
cytochrome b-245 alpha chain |
multiple interactions |
EXP |
AICA ribonucleotide inhibits the reaction [Cadmium Chloride results in increased expression of CYBA protein] |
CTD |
PMID:21195169 |
|
NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721
|
|
G |
Cybb |
cytochrome b-245 beta chain |
multiple interactions |
EXP |
AICA ribonucleotide inhibits the reaction [Cadmium Chloride results in increased expression of CYBB protein] |
CTD |
PMID:21195169 |
|
NCBI chr X:13,360,583...13,392,517
Ensembl chr X:13,359,430...13,392,586
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
multiple interactions |
EXP |
AICA ribonucleotide promotes the reaction [NR1I3 protein results in increased expression of CYP2B10 mRNA]; PRKAA2 protein promotes the reaction [AICA ribonucleotide promotes the reaction [NR1I3 protein results in increased expression of CYP2B10 mRNA]] |
CTD |
PMID:22815988 |
|
NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
ISO |
AICA ribonucleotide inhibits the reaction [EGFR protein results in increased import of Deoxyglucose] |
CTD |
PMID:19625624 |
|
NCBI chr14:91,176,931...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2 subunit alpha |
decreases phosphorylation |
ISO |
AICA ribonucleotide results in decreased phosphorylation of EIF2S1 protein |
CTD |
PMID:22898769 |
|
NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
multiple interactions decreases phosphorylation |
ISO EXP |
AICA ribonucleotide inhibits the reaction [AKT1 protein mutant form results in increased phosphorylation of EIF4EBP1 protein] AICA ribonucleotide results in decreased phosphorylation of EIF4EBP1 protein AICA ribonucleotide inhibits the reaction [Cadmium Chloride results in increased phosphorylation of EIF4EBP1 protein] |
CTD |
PMID:15806154 PMID:21195169 PMID:28041982 |
|
NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984
|
|
G |
Elavl1 |
ELAV like RNA binding protein 1 |
multiple interactions decreases localization |
ISO |
AICA ribonucleotide inhibits the reaction [ELAVL1 protein binds to CCNA2 3' UTR]; AICA ribonucleotide inhibits the reaction [ELAVL1 protein binds to CCNB1 3' UTR] AICA ribonucleotide results in decreased localization of ELAVL1 protein |
CTD |
PMID:12730239 |
|
NCBI chr12:2,640,936...2,684,787
Ensembl chr12:2,645,061...2,684,784
|
|
G |
Foxo1 |
forkhead box O1 |
multiple interactions increases expression increases phosphorylation increases activity |
ISO |
AICA ribonucleotide promotes the reaction [FOXO1 protein results in increased expression of CAT mRNA]; AICA ribonucleotide promotes the reaction [FOXO1 protein results in increased expression of SOD2 mRNA] AICA ribonucleotide results in increased expression of FOXO1 protein AICA ribonucleotide results in increased phosphorylation of FOXO1 protein AICA ribonucleotide results in increased activity of FOXO1 protein |
CTD |
PMID:25065674 |
|
NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790
|
|
G |
Fshb |
follicle stimulating hormone subunit beta |
multiple interactions |
EXP |
AICA ribonucleotide inhibits the reaction [[IGF1 protein co-treated with FSHB protein] results in increased phosphorylation of MAPK1 protein]; AICA ribonucleotide inhibits the reaction [[IGF1 protein co-treated with FSHB protein] results in increased phosphorylation of MAPK3 protein]; AICA ribonucleotide inhibits the reaction [FSHB protein results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:16020477 |
|
NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
decreases expression |
EXP |
AICA ribonucleotide results in decreased expression of G6PC1 mRNA |
CTD |
PMID:19664596 |
|
NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804
|
|
G |
Gpr68 |
G protein-coupled receptor 68 |
multiple interactions |
ISO |
AICA ribonucleotide inhibits the reaction [TNF protein promotes the reaction [Oxygen deficiency results in increased expression of GPR68 mRNA]]; AICA ribonucleotide inhibits the reaction [TNF protein results in increased expression of GPR68 mRNA] |
CTD |
PMID:28174749 |
|
NCBI chr 6:120,135,620...120,166,089
Ensembl chr 6:120,135,436...120,166,089
|
|
G |
Grb2 |
growth factor receptor bound protein 2 |
multiple interactions |
EXP |
GRB2 protein affects the reaction [AICA ribonucleotide results in increased activity of PRKCZ protein] |
CTD |
PMID:11978788 |
|
NCBI chr10:100,881,404...100,949,193
Ensembl chr10:100,869,718...100,949,309
|
|
G |
Gstk1 |
glutathione S-transferase kappa 1 |
increases expression |
ISO |
AICA ribonucleotide results in increased expression of GSTK1 protein |
CTD |
PMID:20980258 |
|
NCBI chr 4:71,118,979...71,123,298
Ensembl chr 4:71,118,896...71,123,292
|
|
G |
Hdac5 |
histone deacetylase 5 |
multiple interactions increases phosphorylation |
ISO |
[AICA ribonucleotide results in increased phosphorylation of HDAC5 protein] which results in increased expression of CTNNB1 mRNA; [AICA ribonucleotide results in increased phosphorylation of HDAC5 protein] which results in increased expression of CTNNB1 protein; AICA ribonucleotide inhibits the reaction [[HDAC5 protein binds to MEF2 protein] which binds to CTNNB1 promoter] |
CTD |
PMID:21454484 |
|
NCBI chr10:87,152,978...87,187,921
Ensembl chr10:87,152,978...87,188,235
|
|
G |
Hnf4a |
hepatocyte nuclear factor 4, alpha |
decreases expression |
ISO |
AICA ribonucleotide results in decreased expression of HNF4A mRNA |
CTD |
PMID:24428821 |
|
NCBI chr 3:152,186,787...152,248,320
Ensembl chr 3:152,186,787...152,248,320
|
|
G |
Hsd3b1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
decreases expression |
EXP |
AICA ribonucleotide results in decreased expression of HSD3B1 mRNA; AICA ribonucleotide results in decreased expression of HSD3B1 protein |
CTD |
PMID:16020477 |
|
NCBI chr 2:186,169,864...186,175,984
Ensembl chr 2:186,169,863...186,175,999
|
|
G |
Igf1 |
insulin-like growth factor 1 |
multiple interactions |
EXP |
AICA ribonucleotide inhibits the reaction [[IGF1 protein co-treated with FSHB protein] results in increased phosphorylation of MAPK1 protein]; AICA ribonucleotide inhibits the reaction [[IGF1 protein co-treated with FSHB protein] results in increased phosphorylation of MAPK3 protein]; AICA ribonucleotide inhibits the reaction [IGF1 protein results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:16020477 |
|
NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions decreases expression |
ISO |
AICA ribonucleotide inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; dorsomorphin inhibits the reaction [AICA ribonucleotide inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]]; dorsomorphin inhibits the reaction [AICA ribonucleotide results in decreased expression of IL1B mRNA] |
CTD |
PMID:24465016 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions decreases expression |
EXP ISO |
AICA ribonucleotide inhibits the reaction [Palmitic Acid results in increased expression of IL6 mRNA] AICA ribonucleotide results in decreased expression of IL6 mRNA AICA ribonucleotide inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; dorsomorphin inhibits the reaction [AICA ribonucleotide inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]]; dorsomorphin inhibits the reaction [AICA ribonucleotide results in decreased expression of IL6 mRNA] |
CTD |
PMID:24465016 PMID:25108154 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Insr |
insulin receptor |
multiple interactions decreases activity decreases expression |
ISO |
5'-amino-5'-deoxyadenosine inhibits the reaction [AICA ribonucleotide results in decreased activity of INSR promoter]; 5'-amino-5'-deoxyadenosine inhibits the reaction [AICA ribonucleotide results in decreased expression of INSR mRNA]; 5'-amino-5'-deoxyadenosine inhibits the reaction [AICA ribonucleotide results in decreased expression of INSR protein]; Dipyridamole inhibits the reaction [AICA ribonucleotide results in decreased activity of INSR promoter]; Dipyridamole inhibits the reaction [AICA ribonucleotide results in decreased expression of INSR mRNA]; Dipyridamole inhibits the reaction [AICA ribonucleotide results in decreased expression of INSR protein] AICA ribonucleotide results in decreased expression of INSR mRNA; AICA ribonucleotide results in decreased expression of INSR protein |
CTD |
PMID:15694368 |
|
NCBI chr12:1,193,193...1,330,976
Ensembl chr12:1,197,100...1,330,883
|
|
G |
Kcnj11 |
potassium inwardly-rectifying channel, subfamily J, member 11 |
affects response to substance |
ISO |
KCNJ11 protein affects the susceptibility to AICA ribonucleotide |
CTD |
PMID:24498880 |
|
NCBI chr 1:96,591,048...96,594,574
Ensembl chr 1:96,591,049...96,594,082
|
|
G |
Klf15 |
Kruppel-like factor 15 |
decreases expression |
ISO |
AICA ribonucleotide results in decreased expression of KLF15 mRNA |
CTD |
PMID:24428821 |
|
NCBI chr 4:122,965,718...122,978,403
Ensembl chr 4:122,965,807...122,978,374
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation decreases phosphorylation |
EXP ISO |
AICA ribonucleotide inhibits the reaction [[IGF1 protein co-treated with FSHB protein] results in increased phosphorylation of MAPK1 protein]; AICA ribonucleotide inhibits the reaction [IGF1 protein results in increased phosphorylation of MAPK1 protein] AICA ribonucleotide results in increased phosphorylation of MAPK1 protein AICA ribonucleotide results in decreased phosphorylation of MAPK1 protein |
CTD |
PMID:16020477 PMID:28038998 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation decreases phosphorylation |
EXP ISO |
AICA ribonucleotide inhibits the reaction [[IGF1 protein co-treated with FSHB protein] results in increased phosphorylation of MAPK3 protein]; AICA ribonucleotide inhibits the reaction [FSHB protein results in increased phosphorylation of MAPK3 protein]; MAPK3 protein affects the reaction [AICA ribonucleotide results in increased uptake of Deoxyglucose]; PTK2B protein affects the reaction [AICA ribonucleotide results in increased activity of MAPK3 protein] AICA ribonucleotide results in increased phosphorylation of MAPK3 protein AICA ribonucleotide results in decreased phosphorylation of MAPK3 protein |
CTD |
PMID:11978788 PMID:16020477 PMID:28038998 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mfn1 |
mitofusin 1 |
multiple interactions |
EXP |
AICA ribonucleotide inhibits the reaction [Acetaminophen results in decreased expression of MFN1 protein]; AICA ribonucleotide inhibits the reaction [Diclofenac results in decreased expression of MFN1 protein] |
CTD |
PMID:27792760 |
|
NCBI chr 2:115,313,380...115,359,651
Ensembl chr 2:115,313,401...115,359,640
|
|
G |
Mfn2 |
mitofusin 2 |
multiple interactions |
EXP |
AICA ribonucleotide inhibits the reaction [Acetaminophen results in decreased expression of MFN2 protein]; AICA ribonucleotide inhibits the reaction [Diclofenac results in decreased expression of MFN2 protein] |
CTD |
PMID:27792760 |
|
NCBI chr 5:158,304,285...158,335,502
Ensembl chr 5:158,304,287...158,335,342
|
|
G |
Mmp13 |
matrix metallopeptidase 13 |
multiple interactions |
ISO |
AICA ribonucleotide inhibits the reaction [TGFB1 protein results in decreased expression of MMP13 protein] |
CTD |
PMID:27688165 |
|
NCBI chr 8:4,497,960...4,508,239
Ensembl chr 8:4,497,960...4,508,239
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
decreases activity |
ISO |
AICA ribonucleotide results in decreased activity of MMP2 protein |
CTD |
PMID:20590612 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
decreases activity |
ISO |
AICA ribonucleotide results in decreased activity of MMP9 protein |
CTD |
PMID:20590612 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
decreases activity decreases phosphorylation multiple interactions |
ISO EXP |
AICA ribonucleotide results in decreased activity of MTOR protein AICA ribonucleotide results in decreased phosphorylation of MTOR protein AICA ribonucleotide promotes the reaction [4-nonylphenol results in decreased phosphorylation of MTOR protein] AICA ribonucleotide promotes the reaction [Cadmium results in decreased phosphorylation of MTOR protein] |
CTD |
PMID:19625624 PMID:21767558 PMID:27363783 PMID:28041982 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Ncf1 |
neutrophil cytosolic factor 1 |
multiple interactions |
EXP |
AICA ribonucleotide inhibits the reaction [Cadmium Chloride results in increased expression of NCF1 protein] |
CTD |
PMID:21195169 |
|
NCBI chr12:22,485,382...22,494,647
Ensembl chr12:22,485,451...22,494,646
|
|
G |
Ncf2 |
neutrophil cytosolic factor 2 |
multiple interactions |
EXP |
AICA ribonucleotide inhibits the reaction [Cadmium Chloride results in increased expression of NCF2 protein] |
CTD |
PMID:21195169 |
|
NCBI chr13:64,955,502...64,986,289
Ensembl chr13:64,955,503...64,986,277
|
|
G |
Ncf4 |
neutrophil cytosolic factor 4 |
multiple interactions |
EXP |
AICA ribonucleotide inhibits the reaction [Cadmium Chloride results in increased expression of NCF4 protein] |
CTD |
PMID:21195169 |
|
NCBI chr 7:109,825,420...109,843,389
Ensembl chr 7:109,826,020...109,843,389
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO |
AICA ribonucleotide inhibits the reaction [Lipopolysaccharides results in increased localization of NFKB1 protein] |
CTD |
PMID:22025971 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
EXP ISO |
AICA ribonucleotide inhibits the reaction [Palmitic Acid results in increased expression of NOS2 mRNA] AICA ribonucleotide inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; dorsomorphin inhibits the reaction [AICA ribonucleotide inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]] |
CTD |
PMID:24465016 PMID:25108154 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nos3 |
nitric oxide synthase 3 |
multiple interactions |
EXP |
AICA ribonucleotide inhibits the reaction [Palmitic Acid inhibits the reaction [Acetylcholine results in increased phosphorylation of NOS3 protein]] |
CTD |
PMID:25108154 |
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Nr0b2 |
nuclear receptor subfamily 0, group B, member 2 |
decreases expression |
ISO |
AICA ribonucleotide results in decreased expression of NR0B2 mRNA |
CTD |
PMID:24428821 |
|
NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
decreases expression |
EXP |
AICA ribonucleotide results in decreased expression of NR1H4 mRNA; AICA ribonucleotide results in decreased expression of NR1H4 protein |
CTD |
PMID:27090119 |
|
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
multiple interactions |
EXP |
AICA ribonucleotide inhibits the reaction [Phenobarbital results in increased localization of and results in increased activity of NR1I3 protein]; AICA ribonucleotide promotes the reaction [NR1I3 protein results in increased expression of CYP2B10 mRNA]; PRKAA2 protein promotes the reaction [AICA ribonucleotide promotes the reaction [NR1I3 protein results in increased expression of CYP2B10 mRNA]] |
CTD |
PMID:20686344 PMID:22815988 |
|
NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
|
|
G |
Nrf1 |
nuclear respiratory factor 1 |
multiple interactions increases expression |
EXP |
dorsomorphin inhibits the reaction [AICA ribonucleotide results in increased expression of NRF1 mRNA] |
CTD |
PMID:20438809 |
|
NCBI chr 4:58,664,932...58,772,328
Ensembl chr 4:58,664,957...58,825,328
|
|
G |
Opa1 |
OPA1, mitochondrial dynamin like GTPase |
multiple interactions |
EXP |
AICA ribonucleotide inhibits the reaction [Acetaminophen results in decreased expression of OPA1 protein]; AICA ribonucleotide inhibits the reaction [Diclofenac results in decreased expression of OPA1 protein] |
CTD |
PMID:27792760 |
|
NCBI chr11:71,108,100...71,185,170
Ensembl chr11:71,109,873...71,185,109
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
EXP |
AICA ribonucleotide inhibits the reaction [Phenylephrine results in decreased expression of PPARA mRNA]; AICA ribonucleotide inhibits the reaction [Phenylephrine results in decreased expression of PPARA protein] |
CTD |
PMID:19699196 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
EXP ISO |
AICA ribonucleotide inhibits the reaction [Palmitic Acid results in decreased expression of PPARG mRNA] AICA ribonucleotide inhibits the reaction [TGFB1 protein results in decreased expression of PPARG protein] |
CTD |
PMID:25108154 PMID:27688165 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions increases expression decreases expression |
EXP ISO |
dorsomorphin inhibits the reaction [AICA ribonucleotide results in increased expression of PPARGC1A mRNA] AICA ribonucleotide results in decreased expression of PPARGC1A mRNA AICA ribonucleotide inhibits the reaction [Glucose results in decreased expression of PPARGC1A protein]; dorsomorphin promotes the reaction [AICA ribonucleotide results in decreased expression of PPARGC1A mRNA] AICA ribonucleotide inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of PPARGC1A protein] |
CTD |
PMID:20438809 PMID:23090186 PMID:24428821 PMID:25522270 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Prkaa1 |
protein kinase AMP-activated catalytic subunit alpha 1 |
increases phosphorylation multiple interactions increases expression increases activity |
EXP ISO |
AICA ribonucleotide results in increased phosphorylation of PRKAA1 protein AICA ribonucleotide inhibits the reaction [Lipopolysaccharides results in decreased phosphorylation of PRKAA1 protein]; dorsomorphin inhibits the reaction [AICA ribonucleotide inhibits the reaction [Lipopolysaccharides results in decreased phosphorylation of PRKAA1 protein]]; dorsomorphin inhibits the reaction [AICA ribonucleotide results in increased phosphorylation of PRKAA1 protein] AICA ribonucleotide promotes the reaction [Quercetin results in increased phosphorylation of and results in increased activity of PRKAA1 protein]; AICA ribonucleotide results in increased phosphorylation of and results in increased activity of PRKAA1 protein; PRKAA1 protein affects the reaction [AICA ribonucleotide results in increased expression of CYP4F2 mRNA]; Quercetin promotes the reaction [AICA ribonucleotide results in increased phosphorylation of and results in increased activity of PRKAA1 protein] AICA ribonucleotide results in increased expression of PRKAA1 protein modified form [AICA ribonucleotide results in increased phosphorylation of PRKAA1 protein] which results in decreased secretion of Progesterone; AICA ribonucleotide inhibits the reaction [Cadmium Chloride results in decreased phosphorylation of PRKAA1 protein]; AICA ribonucleotide inhibits the reaction [Sodium Chloride, Dietary results in decreased phosphorylation of and results in decreased activity of PRKAA1 protein]; AICA ribonucleotide inhibits the reaction [Sodium Chloride, Dietary results in increased expression of PRKAA1 mRNA] AICA ribonucleotide results in increased activity of PRKAA1 protein |
CTD |
PMID:12519745 PMID:16020477 PMID:16873680 PMID:19293639 PMID:20349193 PMID:21195169 PMID:21205922 PMID:23266269 PMID:24465016 PMID:25743752 PMID:28298333 More...
|
|
NCBI chr 2:54,240,298...54,275,978
Ensembl chr 2:54,240,137...54,275,978
|
|
G |
Prkaa2 |
protein kinase AMP-activated catalytic subunit alpha 2 |
multiple interactions increases phosphorylation |
ISO EXP |
AICA ribonucleotide results in increased phosphorylation of and results in increased activity of PRKAA2 protein; PRKAA2 protein affects the reaction [AICA ribonucleotide results in increased expression of CYP4F2 mRNA] PRKAA2 protein promotes the reaction [AICA ribonucleotide promotes the reaction [NR1I3 protein results in increased expression of CYP2B10 mRNA]] AICA ribonucleotide results in increased phosphorylation of PRKAA2 protein PRKAA2 protein affects the reaction [AICA ribonucleotide inhibits the reaction [AKT1 protein mutant form affects the susceptibility to Glucose deficiency]]; PRKAA2 protein affects the reaction [AICA ribonucleotide results in increased expression of CTNNB1 mRNA]; PRKAA2 protein affects the reaction [AICA ribonucleotide results in increased expression of CTNNB1 protein] |
CTD |
PMID:15806154 PMID:16873680 PMID:18482975 PMID:21205922 PMID:21454484 PMID:22815988 More...
|
|
NCBI chr 5:119,807,992...119,879,987
Ensembl chr 5:119,813,226...119,879,543
|
|
G |
Prkcz |
protein kinase C, zeta |
multiple interactions increases activity |
EXP |
1-Butanol inhibits the reaction [AICA ribonucleotide results in increased activity of PRKCZ protein]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [AICA ribonucleotide results in increased activity of PRKCZ protein]; Genistein inhibits the reaction [AICA ribonucleotide results in increased activity of PRKCZ protein]; GRB2 protein affects the reaction [AICA ribonucleotide results in increased activity of PRKCZ protein]; PTK2B protein affects the reaction [AICA ribonucleotide results in increased activity of PRKCZ protein] |
CTD |
PMID:11978788 |
|
NCBI chr 5:165,817,786...165,930,386
Ensembl chr 5:165,819,466...165,930,367
|
|
G |
Pten |
phosphatase and tensin homolog |
increases response to substance |
ISO |
PTEN protein results in increased susceptibility to AICA ribonucleotide |
CTD |
PMID:19625624 |
|
NCBI chr 1:230,631,303...230,696,754
Ensembl chr 1:230,630,338...230,696,838
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
AICA ribonucleotide inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein] |
CTD |
PMID:22025971 |
|
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Ptk2b |
protein tyrosine kinase 2 beta |
multiple interactions |
EXP |
AICA ribonucleotide results in increased phosphorylation of and results in increased activity of PTK2B protein; PTK2B protein affects the reaction [AICA ribonucleotide results in increased activity of MAPK3 protein]; PTK2B protein affects the reaction [AICA ribonucleotide results in increased activity of PRKCZ protein] |
CTD |
PMID:11978788 |
|
NCBI chr15:40,360,722...40,481,235
Ensembl chr15:40,360,723...40,481,282
|
|
G |
Rac1 |
Rac family small GTPase 1 |
multiple interactions |
EXP |
AICA ribonucleotide inhibits the reaction [Cadmium Chloride results in increased expression of RAC1 protein] |
CTD |
PMID:21195169 |
|
NCBI chr12:11,037,028...11,057,251
Ensembl chr12:11,036,698...11,057,251
|
|
G |
Raf1 |
Raf-1 proto-oncogene, serine/threonine kinase |
multiple interactions |
EXP |
RAF1 protein affects the reaction [AICA ribonucleotide results in increased uptake of Deoxyglucose] |
CTD |
PMID:11978788 |
|
NCBI chr 4:148,679,534...148,740,265
Ensembl chr 4:148,679,530...148,740,317
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO EXP |
AICA ribonucleotide inhibits the reaction [Streptozocin results in increased phosphorylation of and results in increased activity of RELA protein] AICA ribonucleotide inhibits the reaction [Palmitic Acid results in increased phosphorylation of RELA protein]; dorsomorphin inhibits the reaction [AICA ribonucleotide inhibits the reaction [Palmitic Acid results in increased phosphorylation of RELA protein]]; Niacinamide inhibits the reaction [AICA ribonucleotide inhibits the reaction [Palmitic Acid results in increased phosphorylation of RELA protein]] |
CTD |
PMID:22058332 PMID:25108154 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rps6 |
ribosomal protein S6 |
decreases phosphorylation |
ISO |
AICA ribonucleotide results in decreased phosphorylation of RPS6 protein |
CTD |
PMID:19625624 |
|
NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602 Ensembl chr 5:101,371,136...101,374,602
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
multiple interactions decreases phosphorylation increases phosphorylation |
EXP |
AICA ribonucleotide inhibits the reaction [Cadmium Chloride results in increased phosphorylation of RPS6KB1 protein]; naringin inhibits the reaction [AICA ribonucleotide results in increased phosphorylation of RPS6KB1 protein] AICA ribonucleotide results in decreased phosphorylation of RPS6KB1 protein |
CTD |
PMID:15342961 PMID:21195169 PMID:28041982 |
|
NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions increases expression |
ISO EXP |
AICA ribonucleotide inhibits the reaction [Glucose results in decreased expression of SIRT1 protein]; AICA ribonucleotide inhibits the reaction [Lipopolysaccharides results in decreased expression of SIRT1 protein]; AICA ribonucleotide inhibits the reaction [Streptozocin results in decreased activity of SIRT1 protein]; dorsomorphin inhibits the reaction [AICA ribonucleotide inhibits the reaction [Lipopolysaccharides results in decreased expression of SIRT1 protein]]; dorsomorphin inhibits the reaction [AICA ribonucleotide results in increased expression of SIRT1 protein] AICA ribonucleotide inhibits the reaction [TGFB1 protein results in decreased expression of SIRT1 protein] [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased susceptibility to AICA ribonucleotide |
CTD |
PMID:22058332 PMID:23090186 PMID:24465016 PMID:25108154 PMID:27688165 |
|
NCBI chr20:25,307,143...25,329,260
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Slc10a1 |
solute carrier family 10 member 1 |
decreases expression |
EXP |
AICA ribonucleotide results in decreased expression of SLC10A1 mRNA |
CTD |
PMID:27090119 |
|
NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670
|
|
G |
Slc15a1 |
solute carrier family 15 member 1 |
decreases activity |
ISO |
AICA ribonucleotide results in decreased activity of SLC15A1 protein |
CTD |
PMID:22108913 |
|
NCBI chr15:98,537,641...98,582,544
Ensembl chr15:98,537,641...98,582,545
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
multiple interactions increases localization |
EXP ISO |
1-Butanol inhibits the reaction [AICA ribonucleotide results in increased localization of SLC2A4 protein]; Genistein inhibits the reaction [AICA ribonucleotide results in increased localization of SLC2A4 protein]; U 0126 inhibits the reaction [AICA ribonucleotide results in increased localization of SLC2A4 protein]; wortmannin inhibits the reaction [AICA ribonucleotide results in increased localization of SLC2A4 protein] AICA ribonucleotide inhibits the reaction [Palmitates results in decreased expression of SLC2A4 mRNA] |
CTD |
PMID:11978788 PMID:21802492 |
|
NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565
|
|
G |
Slco1a4 |
solute carrier organic anion transporter family, member 1a4 |
decreases expression |
EXP |
AICA ribonucleotide results in decreased expression of SLCO1A2 mRNA |
CTD |
PMID:27090119 |
|
NCBI chr 4:174,710,004...174,764,810
Ensembl chr 4:174,710,004...175,254,573
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions increases expression |
ISO |
AICA ribonucleotide promotes the reaction [FOXO1 protein results in increased expression of SOD2 mRNA] AICA ribonucleotide results in increased expression of SOD2 mRNA; AICA ribonucleotide results in increased expression of SOD2 protein |
CTD |
PMID:25065674 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions increases expression |
ISO |
[AICA ribonucleotide co-treated with Sirolimus] results in increased expression of SQSTM1 protein; TP53 gene mutant form promotes the reaction [AICA ribonucleotide results in increased expression of SQSTM1 protein] |
CTD |
PMID:33070465 |
|
NCBI chr10:34,525,517...34,536,685
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Stk11 |
serine/threonine kinase 11 |
multiple interactions |
ISO |
AICA ribonucleotide inhibits the reaction [TGFB1 protein results in decreased phosphorylation of STK11 protein] |
CTD |
PMID:27688165 |
|
NCBI chr 7:9,574,553...9,591,315
Ensembl chr 7:9,575,269...9,591,315
|
|
G |
Tbc1d1 |
TBC1 domain family member 1 |
multiple interactions |
ISO |
AICA ribonucleotide inhibits the reaction [INS1 protein results in increased phosphorylation of TBC1D1 protein] |
CTD |
PMID:26627467 |
|
NCBI chr14:43,936,820...44,135,133
Ensembl chr14:43,935,636...44,136,499
|
|
G |
Tbc1d4 |
TBC1 domain family, member 4 |
multiple interactions |
ISO |
AICA ribonucleotide inhibits the reaction [INS1 protein results in increased phosphorylation of TBC1D4 protein] |
CTD |
PMID:24343960 PMID:26627467 |
|
NCBI chr15:78,256,030...78,434,168
Ensembl chr15:78,257,121...78,434,265
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
AICA ribonucleotide inhibits the reaction [TGFB1 protein results in decreased expression of MMP13 protein]; AICA ribonucleotide inhibits the reaction [TGFB1 protein results in decreased expression of PPARG protein]; AICA ribonucleotide inhibits the reaction [TGFB1 protein results in decreased expression of SIRT1 protein]; AICA ribonucleotide inhibits the reaction [TGFB1 protein results in decreased phosphorylation of STK11 protein]; AICA ribonucleotide inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]; AICA ribonucleotide inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 protein]; AICA ribonucleotide inhibits the reaction [TGFB1 protein results in increased expression of TIMP1 protein] |
CTD |
PMID:27688165 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
multiple interactions |
ISO |
AICA ribonucleotide inhibits the reaction [TGFB1 protein results in increased expression of TIMP1 protein] |
CTD |
PMID:27688165 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO EXP |
AICA ribonucleotide inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein] AICA ribonucleotide inhibits the reaction [TNF protein promotes the reaction [Oxygen deficiency results in increased expression of GPR68 mRNA]]; AICA ribonucleotide inhibits the reaction [TNF protein results in increased expression of GPR68 mRNA] AICA ribonucleotide inhibits the reaction [Palmitic Acid results in increased expression of TNF mRNA] |
CTD |
PMID:22025971 PMID:25108154 PMID:28174749 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfrsf1a |
TNF receptor superfamily member 1A |
multiple interactions |
ISO |
AICA ribonucleotide inhibits the reaction [Lipopolysaccharides results in increased expression of TNFRSF1A protein] |
CTD |
PMID:22025971 |
|
NCBI chr 4:158,150,815...158,163,592
Ensembl chr 4:158,150,820...158,163,591
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions increases phosphorylation |
ISO |
[Resveratrol co-treated with AICA ribonucleotide] inhibits the reaction [Glucose results in increased expression of TP53 protein]; AICA ribonucleotide inhibits the reaction [TP53 gene mutant form results in increased expression of CPT1A protein]; AICA ribonucleotide promotes the reaction [TP53 gene mutant form results in increased phosphorylation of ULK1 protein]; TP53 gene mutant form promotes the reaction [AICA ribonucleotide results in increased expression of SQSTM1 protein]; TP53 gene mutant form promotes the reaction [AICA ribonucleotide results in increased phosphorylation of ULK1 protein] AICA ribonucleotide results in increased phosphorylation of TP53 protein |
CTD |
PMID:26188290 PMID:33070465 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Txnip |
thioredoxin interacting protein |
multiple interactions |
ISO |
AICA ribonucleotide inhibits the reaction [Palmitic Acid results in increased expression of TXNIP protein] |
CTD |
PMID:29031535 |
|
NCBI chr 2:184,093,079...184,096,882
Ensembl chr 2:184,092,991...184,096,886
|
|
G |
Ucp2 |
uncoupling protein 2 |
multiple interactions |
EXP |
AICA ribonucleotide inhibits the reaction [Indican results in decreased expression of UCP2 mRNA] |
CTD |
PMID:25703824 |
|
NCBI chr 1:154,839,242...154,845,612
Ensembl chr 1:154,839,209...154,845,611
|
|
G |
Ulk1 |
unc-51 like autophagy activating kinase 1 |
multiple interactions |
ISO |
AICA ribonucleotide promotes the reaction [TP53 gene mutant form results in increased phosphorylation of ULK1 protein]; AICA ribonucleotide results in increased expression of and results in increased phosphorylation of ULK1 protein; TP53 gene mutant form promotes the reaction [AICA ribonucleotide results in increased phosphorylation of ULK1 protein] |
CTD |
PMID:33070465 |
|
NCBI chr12:45,851,710...45,877,966
Ensembl chr12:45,851,710...45,877,966
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
AICA ribonucleotide inhibits the reaction [[nickel chloride results in increased abundance of Nickel] which results in increased secretion of VEGFA protein] |
CTD |
PMID:30724446 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Xpo1 |
exportin 1 |
multiple interactions |
ISO |
AICA ribonucleotide promotes the reaction [ABL1 protein mutant form binds to XPO1 protein]; AICA ribonucleotide promotes the reaction [XPO1 protein binds to BECN1 protein]; AICA ribonucleotide promotes the reaction [XPO1 protein binds to YWHAQ protein] |
CTD |
PMID:33070465 |
|
NCBI chr14:97,233,263...97,275,536
Ensembl chr14:97,233,270...97,275,498
|
|
G |
Ywhaq |
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, theta |
multiple interactions |
ISO |
AICA ribonucleotide promotes the reaction [ABL1 protein mutant form binds to YWHAQ protein]; AICA ribonucleotide promotes the reaction [XPO1 protein binds to YWHAQ protein] |
CTD |
PMID:33070465 |
|
NCBI chr 6:40,935,714...40,966,240
Ensembl chr 6:40,935,949...40,966,273
|
|
|
G |
Alb |
albumin |
affects binding |
ISO |
Emtricitabine binds to ALB protein |
CTD |
PMID:15814459 PMID:16336266 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions |
ISO |
[Emtricitabine co-treated with Tenofovir] results in increased expression of CDKN1A protein |
CTD |
PMID:31545371 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Dck |
deoxycytidine kinase |
multiple interactions affects binding |
ISO |
DCK protein results in increased phosphorylation of and results in increased activity of Emtricitabine Emtricitabine binds to DCK protein |
CTD |
PMID:17530837 |
|
NCBI chr14:19,305,218...19,326,247
Ensembl chr14:19,305,218...19,326,247
|
|
G |
Prkn |
parkin RBR E3 ubiquitin protein ligase |
decreases expression multiple interactions |
ISO |
Emtricitabine results in decreased expression of PRKN protein [Emtricitabine co-treated with Tenofovir] results in decreased expression of PRKN protein |
CTD |
PMID:31545371 |
|
NCBI chr 1:48,688,651...49,882,520
Ensembl chr 1:48,690,556...49,882,555
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
ISO |
[Emtricitabine co-treated with Tenofovir] results in increased expression of TP53 protein |
CTD |
PMID:31545371 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
|
G |
Apex1 |
apurinic/apyrimidinic endodeoxyribonuclease 1 |
increases response to substance decreases response to substance |
ISO |
APEX1 protein mutant form results in increased susceptibility to Floxuridine APEX1 protein results in decreased susceptibility to Floxuridine |
CTD |
PMID:19470598 PMID:22194930 |
|
NCBI chr15:24,144,595...24,146,785
Ensembl chr15:24,144,362...24,146,785
|
|
G |
Atr |
ATR serine/threonine kinase |
decreases response to substance |
ISO |
ATR protein results in decreased susceptibility to Floxuridine |
CTD |
PMID:21613406 PMID:22194930 |
|
NCBI chr 8:96,426,704...96,524,152
Ensembl chr 8:96,426,724...96,524,136
|
|
G |
C1qbp |
complement C1q binding protein |
decreases response to substance |
ISO |
C1QBP protein results in decreased susceptibility to Floxuridine |
CTD |
PMID:25354864 |
|
NCBI chr10:55,699,954...55,704,605
Ensembl chr10:55,699,954...55,704,649
|
|
G |
Chek1 |
checkpoint kinase 1 |
multiple interactions |
ISO |
Floxuridine results in increased phosphorylation of and results in increased activity of CHEK1 protein |
CTD |
PMID:21613406 PMID:22194930 |
|
NCBI chr 8:36,420,565...36,443,477
Ensembl chr 8:36,420,569...36,441,009
|
|
G |
Chek2 |
checkpoint kinase 2 |
multiple interactions increases activity |
ISO |
Floxuridine results in increased phosphorylation of and results in increased activity of CHEK2 protein Floxuridine results in increased activity of CHEK2 protein |
CTD |
PMID:21613406 PMID:22194930 |
|
NCBI chr12:45,788,823...45,821,382
Ensembl chr12:45,788,827...45,821,286
|
|
G |
Mlh1 |
mutL homolog 1 |
multiple interactions decreases response to substance |
ISO |
olaparib inhibits the reaction [MLH1 protein results in decreased susceptibility to Floxuridine] |
CTD |
PMID:22194930 |
|
NCBI chr 8:111,196,468...111,233,721
Ensembl chr 8:111,196,468...111,233,617
|
|
G |
Msh2 |
mutS homolog 2 |
multiple interactions decreases response to substance |
ISO |
olaparib inhibits the reaction [MSH2 protein results in decreased susceptibility to Floxuridine] |
CTD |
PMID:22194930 |
|
NCBI chr 6:6,813,793...6,872,960
Ensembl chr 6:6,813,795...6,872,938
|
|
G |
Mthfr |
methylenetetrahydrofolate reductase |
affects response to substance |
ISO |
MTHFR protein affects the susceptibility to Floxuridine |
CTD |
PMID:18202788 |
|
NCBI chr 5:158,465,248...158,484,999
Ensembl chr 5:158,465,296...158,483,797
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
decreases response to substance |
ISO |
PARP1 protein results in decreased susceptibility to Floxuridine |
CTD |
PMID:21613406 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Timp3 |
TIMP metallopeptidase inhibitor 3 |
affects response to substance decreases response to substance |
ISO |
TIMP3 protein affects the susceptibility to Floxuridine TIMP3 gene modified form results in decreased susceptibility to Floxuridine |
CTD |
PMID:18202788 |
|
NCBI chr 7:17,520,827...17,571,871
Ensembl chr 7:17,521,919...17,571,839
|
|
G |
Tk1 |
thymidine kinase 1 |
increases expression |
ISO |
Floxuridine results in increased expression of TK1 protein |
CTD |
PMID:16951200 |
|
NCBI chr10:103,034,755...103,046,125
Ensembl chr10:103,031,521...103,046,920
|
|
G |
Tp53 |
tumor protein p53 |
increases expression |
ISO |
Floxuridine results in increased expression of TP53 protein |
CTD |
PMID:19015155 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tyms |
thymidylate synthetase |
affects response to substance increases response to substance decreases response to substance |
ISO |
TYMS protein affects the susceptibility to Floxuridine TYMS results in increased susceptibility to Floxuridine TYMS protein results in decreased susceptibility to Floxuridine |
CTD |
PMID:2537495 PMID:10482907 PMID:15040806 PMID:17018589 |
|
NCBI chr 9:113,313,454...113,329,551
Ensembl chr 9:113,313,452...113,329,536
|
|
G |
Ung |
uracil-DNA glycosylase |
affects expression increases response to substance affects stability |
ISO |
Floxuridine affects the expression of UNG mRNA; Floxuridine affects the expression of UNG protein UNG protein results in increased susceptibility to Floxuridine Floxuridine affects the stability of UNG protein alternative form |
CTD |
PMID:16951200 |
|
NCBI chr12:42,485,276...42,494,217
Ensembl chr12:42,485,276...42,494,206
|
|
G |
Xrcc1 |
X-ray repair cross complementing 1 |
decreases response to substance |
ISO |
XRCC1 protein results in decreased susceptibility to Floxuridine |
CTD |
PMID:21613406 PMID:22194930 |
|
NCBI chr 1:80,140,495...80,168,705
Ensembl chr 1:80,141,207...80,168,701
|
|
G |
Xrcc4 |
X-ray repair cross complementing 4 |
decreases response to substance |
ISO |
XRCC4 results in decreased susceptibility to Floxuridine |
CTD |
PMID:21785230 |
|
NCBI chr 2:20,948,464...21,197,705
Ensembl chr 2:20,951,200...21,197,808
|
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression |
ISO |
Flucytosine results in decreased expression of BCL2 protein |
CTD |
PMID:15592511 |
|
NCBI chr13:22,689,783...22,853,920
|
|
G |
Mdm2 |
MDM2 proto-oncogene |
increases expression |
ISO |
Flucytosine results in increased expression of MDM2 protein |
CTD |
PMID:15592511 |
|
NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915
|
|
G |
Tp53 |
tumor protein p53 |
increases expression |
ISO |
Flucytosine results in increased expression of TP53 protein |
CTD |
PMID:15592511 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
|
G |
Acadsb |
acyl-CoA dehydrogenase, short/branched chain |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of ACADSB mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 1:186,188,939...186,227,796
Ensembl chr 1:186,188,987...186,230,379
|
|
G |
Acsl6 |
acyl-CoA synthetase long-chain family member 6 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of ACSL6 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr10:38,439,914...38,501,182
Ensembl chr10:38,440,080...38,498,757
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
decreases expression |
ISO |
Lamivudine results in decreased expression of ACTA2 protein |
CTD |
PMID:11738102 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of ADIPOQ mRNA |
CTD |
PMID:16931933 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Aebp1 |
AE binding protein 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of AEBP1 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of AEBP1 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of AEBP1 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr14:80,738,800...80,748,878
Ensembl chr14:80,738,892...80,748,877
|
|
G |
Afap1 |
actin filament associated protein 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of AFAP1 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr14:74,743,322...74,856,295
Ensembl chr14:74,743,320...74,856,263
|
|
G |
Alb |
albumin |
affects binding |
ISO |
Lamivudine binds to ALB protein |
CTD |
PMID:15814459 PMID:16336266 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Alox5ap |
arachidonate 5-lipoxygenase activating protein |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of ALOX5AP mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of ALOX5AP mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of ALOX5AP mRNA |
CTD |
PMID:16931933 |
|
NCBI chr12:5,748,941...5,772,986
Ensembl chr12:5,748,944...5,772,986
|
|
G |
Aqp9 |
aquaporin 9 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of AQP9 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 8:71,797,231...71,837,485
Ensembl chr 8:71,797,234...71,837,395
|
|
G |
Arpp21 |
cAMP regulated phosphoprotein 21 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of ARPP21 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of ARPP21 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of ARPP21 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 8:112,034,636...112,199,273
Ensembl chr 8:112,034,642...112,194,297
|
|
G |
Asic2 |
acid sensing ion channel subunit 2 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of ASIC2 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of ASIC2 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr10:65,870,592...66,940,577
Ensembl chr10:65,870,594...66,940,424
|
|
G |
Asns |
asparagine synthetase (glutamine-hydrolyzing) |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of ASNS mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 4:35,784,995...35,803,474
Ensembl chr 4:35,785,237...35,803,423
|
|
G |
Ass1 |
argininosuccinate synthase 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of ASS1 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 3:14,747,355...14,796,909
Ensembl chr 3:14,747,368...14,796,903
|
|
G |
Atf3 |
activating transcription factor 3 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of ATF3 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631
|
|
G |
Atp2a2 |
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of ATP2A2 mRNA |
CTD |
PMID:11706060 |
|
NCBI chr12:34,072,710...34,122,142
Ensembl chr12:34,072,683...34,122,101
|
|
G |
Atp5f1c |
ATP synthase F1 subunit gamma |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of ATP5C1 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr17:68,423,927...68,446,169
Ensembl chr17:68,423,909...68,608,367
|
|
G |
Atp5mc3 |
ATP synthase membrane subunit c locus 3 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of ATP5G3 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 3:58,810,535...58,813,185
Ensembl chr 3:58,810,535...58,814,279
|
|
G |
Atp5mf |
ATP synthase membrane subunit f |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of ATP5J2 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr12:9,421,665...9,428,236
Ensembl chr12:9,421,579...9,428,236
|
|
G |
Atp5pd |
ATP synthase peripheral stalk subunit d |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of ATP5H mRNA |
CTD |
PMID:18313992 |
|
NCBI chr10:100,657,700...100,662,960
Ensembl chr10:100,657,708...100,663,479
|
|
G |
Atp5pf |
ATP synthase peripheral stalk subunit F6 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of ATP5J mRNA |
CTD |
PMID:18313992 |
|
NCBI chr11:23,881,594...23,889,581
Ensembl chr11:23,881,592...23,889,119
|
|
G |
Atp5po |
ATP synthase peripheral stalk subunit OSCP |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of ATP5O mRNA |
CTD |
PMID:18313992 |
|
NCBI chr11:31,165,218...31,171,530
Ensembl chr11:31,165,217...31,171,592
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of BCL2 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr13:22,689,783...22,853,920
|
|
G |
Bnip3l |
BCL2 interacting protein 3 like |
increases expression |
ISO |
Lamivudine results in increased expression of BNIP3L protein |
CTD |
PMID:23640862 |
|
NCBI chr15:41,174,594...41,197,730
Ensembl chr15:41,174,594...41,197,803
|
|
G |
C1r |
complement C1r |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of C1R mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of C1R mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 4:157,412,718...157,423,483
Ensembl chr 4:157,412,692...157,423,484
|
|
G |
C3ar1 |
complement C3a receptor 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of C3AR1 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of C3AR1 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of C3AR1 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 4:156,074,747...156,084,680
Ensembl chr 4:156,075,389...156,084,701
|
|
G |
Cars |
cysteinyl-tRNA synthetase |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of CARS1 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 1:198,753,689...198,796,016
Ensembl chr 1:198,753,691...198,795,941
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
[efavirenz co-treated with Lamivudine co-treated with Tenofovir] results in decreased activity of CAT protein |
CTD |
PMID:34118364 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccna2 |
cyclin A2 |
multiple interactions decreases expression |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of CCNA2 mRNA Lamivudine results in decreased expression of CCNA2 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577
|
|
G |
Ccnc |
cyclin C |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of CCNC mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 5:35,266,828...35,284,943
Ensembl chr 5:35,266,823...35,296,584
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of CCND1 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccnd2 |
cyclin D2 |
decreases expression multiple interactions |
ISO |
Lamivudine results in decreased expression of CCND2 mRNA [Zidovudine co-treated with Lamivudine] results in decreased expression of CCND2 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495
|
|
G |
Ccne2 |
cyclin E2 |
multiple interactions decreases expression |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of CCNE2 mRNA Lamivudine results in decreased expression of CCNE2 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 5:24,285,078...24,298,258
Ensembl chr 5:24,284,922...24,297,632
|
|
G |
Cd36 |
CD36 molecule |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of CD36 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of CD36 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903
|
|
G |
Cd44 |
CD44 molecule (Indian blood group) |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of CD44 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620
|
|
G |
Cd83 |
CD83 molecule |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of CD83 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr17:20,887,309...20,907,009
Ensembl chr17:20,887,309...20,907,083
|
|
G |
Cdk7 |
cyclin-dependent kinase 7 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of CDK7 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 2:31,840,545...31,865,447
Ensembl chr 2:31,840,558...31,865,383
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
decreases expression multiple interactions |
ISO |
Lamivudine results in decreased expression of CDKN1A mRNA [Zidovudine co-treated with Lamivudine] results in decreased expression of CDKN1A mRNA |
CTD |
PMID:15784690 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of CDKN1B mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cdkn1c |
cyclin-dependent kinase inhibitor 1C |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of CDKN1C mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 1:198,655,394...198,658,097
Ensembl chr 1:198,655,407...198,658,048
|
|
G |
Cdkn2c |
cyclin-dependent kinase inhibitor 2C |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of CDKN2C mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 5:124,411,123...124,416,278
Ensembl chr 5:124,411,124...124,416,278
|
|
G |
Cfd |
complement factor D |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of CFD mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 7:9,813,148...9,814,871
Ensembl chr 7:9,813,150...9,815,053
|
|
G |
Cidec |
cell death-inducing DFFA-like effector c |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of CIDEC mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of CIDEC mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 4:146,569,288...146,582,173
Ensembl chr 4:146,569,289...146,582,173
|
|
G |
Clcn3 |
chloride voltage-gated channel 3 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of CLCN3 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of CLCN3 mRNA; [Zidovudine co-treated with Lamivudine] results in decreased expression of CLCN3 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr16:29,127,419...29,200,133
Ensembl chr16:29,127,419...29,200,119
|
|
G |
Clec2dl1 |
C-type lectin domain family 2 member D-like 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of CLEC2I mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 4:162,263,578...162,274,882
Ensembl chr 4:162,263,639...162,274,880
|
|
G |
Col3a1 |
collagen type III alpha 1 chain |
decreases expression |
ISO |
Lamivudine results in decreased expression of COL3A1 protein |
CTD |
PMID:11738102 |
|
NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547
|
|
G |
Comt |
catechol-O-methyltransferase |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of COMT mRNA |
CTD |
PMID:15784690 |
|
NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642
|
|
G |
Cox5a |
cytochrome c oxidase subunit 5A |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of COX5A mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 8:57,922,374...57,933,781
Ensembl chr 8:57,922,290...57,933,781
|
|
G |
Cox5b |
cytochrome c oxidase subunit 5B |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of COX5B mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 9:38,921,980...38,923,806
Ensembl chr 9:38,921,967...38,925,052
|
|
G |
Cox6a1 |
cytochrome c oxidase subunit 6A1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of COX6A1 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr12:41,261,983...41,265,037
Ensembl chr12:41,261,967...41,265,041
|
|
G |
Cox6c |
cytochrome c oxidase subunit 6C |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of COX6C mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 7:67,129,265...67,142,001
Ensembl chr 7:67,111,024...67,141,963
|
|
G |
Cox7c |
cytochrome c oxidase subunit 7C |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of COX7C mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 2:16,841,771...16,843,796
Ensembl chr 2:16,840,837...16,843,760
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of CPT1A mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Crat |
carnitine O-acetyltransferase |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of CRAT mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 3:13,675,684...13,689,282
Ensembl chr 3:13,675,684...13,689,255
|
|
G |
Cul7 |
cullin 7 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of CUL7 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 9:14,319,102...14,333,035
Ensembl chr 9:14,319,108...14,332,741
|
|
G |
Cyb5a |
cytochrome b5 type A |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of CYB5A mRNA |
CTD |
PMID:18313992 |
|
NCBI chr18:78,213,067...78,245,677
Ensembl chr18:78,202,342...78,258,535 Ensembl chr18:78,202,342...78,258,535
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of CYP11A1 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338
|
|
G |
Dck |
deoxycytidine kinase |
multiple interactions |
ISO |
DCK protein results in increased phosphorylation of and results in increased activity of Lamivudine |
CTD |
PMID:17530837 |
|
NCBI chr14:19,305,218...19,326,247
Ensembl chr14:19,305,218...19,326,247
|
|
G |
Dcn |
decorin |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of DCN mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of DCN mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 7:32,281,252...32,321,291
Ensembl chr 7:32,281,252...32,321,270
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression multiple interactions |
ISO |
Lamivudine results in increased expression of DDIT3 mRNA [Zidovudine co-treated with Lamivudine] results in increased expression of DDIT3 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Dhfr |
dihydrofolate reductase |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of DHFR mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 2:23,585,876...23,611,199
Ensembl chr 2:23,586,031...23,613,713
|
|
G |
Diablo |
diablo, IAP-binding mitochondrial protein |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of DIABLO mRNA |
CTD |
PMID:18313992 |
|
NCBI chr12:33,055,784...33,070,400
Ensembl chr12:33,055,263...33,070,387
|
|
G |
Dlst |
dihydrolipoamide S-succinyltransferase |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of DLST mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 6:104,758,511...104,783,296
Ensembl chr 6:104,758,631...104,783,296
|
|
G |
Dnaja3 |
DnaJ heat shock protein family (Hsp40) member A3 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of DNAJA3 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr10:10,855,510...10,880,175
Ensembl chr10:10,854,732...10,880,161
|
|
G |
Dusp3 |
dual specificity phosphatase 3 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of DUSP3 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of DUSP3 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of DUSP3 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr10:86,920,014...86,933,739
Ensembl chr10:86,920,014...86,933,962
|
|
G |
Echs1 |
enoyl-CoA hydratase, short chain 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of ECHS1 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 1:194,895,036...194,903,863
Ensembl chr 1:194,895,036...194,903,884
|
|
G |
Eci1 |
enoyl-CoA delta isomerase 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of ECI1 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr10:13,456,715...13,470,061
Ensembl chr10:13,456,563...13,470,061
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions increases secretion |
ISO |
coenzyme Q10 inhibits the reaction [Lamivudine results in increased secretion of EDN1 protein] |
CTD |
PMID:23640862 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of EIF4EBP1 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984
|
|
G |
Elovl3 |
ELOVL fatty acid elongase 3 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of ELOVL3 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of ELOVL3 mRNA; [Zidovudine co-treated with Lamivudine] results in decreased expression of ELOVL3 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 1:244,997,287...245,001,115
Ensembl chr 1:244,997,287...245,001,115
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of ESR2 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of ESR2 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Etv6 |
ETS variant transcription factor 6 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of ETV6 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of ETV6 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of ETV6 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 4:166,849,031...167,085,211
Ensembl chr 4:166,847,686...167,084,992
|
|
G |
Fads2 |
fatty acid desaturase 2 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of FADS2 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of FADS2 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 1:206,707,384...206,747,333
Ensembl chr 1:206,708,783...206,748,789
|
|
G |
Faim |
Fas apoptotic inhibitory molecule |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of FAIM mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of FAIM mRNA; [Zidovudine co-treated with Lamivudine] results in decreased expression of FAIM mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 8:99,543,877...99,569,499
Ensembl chr 8:99,542,405...99,560,562
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions |
ISO |
[Stavudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of FASN mRNA; [Stavudine co-treated with Lamivudine] results in increased expression of FASN mRNA; [Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of FASN mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of FASN mRNA |
CTD |
PMID:11741158 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Fdxr |
ferredoxin reductase |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of FDXR mRNA |
CTD |
PMID:18313992 |
|
NCBI chr10:100,507,863...100,516,649
Ensembl chr10:100,507,865...100,516,658
|
|
G |
Fh |
fumarate hydratase |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of FH1 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr13:87,524,331...87,550,215
Ensembl chr13:87,524,337...87,550,266
|
|
G |
G0s2 |
G0/G1switch 2 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of G0S2 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of G0S2 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr13:104,806,351...104,807,263
Ensembl chr13:104,806,156...104,807,451
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of G6PC mRNA |
CTD |
PMID:16931933 |
|
NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804
|
|
G |
Ganc |
glucosidase, alpha; neutral C |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of GANC mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of GANC mRNA; [Zidovudine co-treated with Lamivudine] results in decreased expression of GANC mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 3:107,353,369...107,406,104
Ensembl chr 3:107,353,369...107,405,241
|
|
G |
Gars1 |
glycyl-tRNA synthetase 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of GARS1 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 4:84,171,596...84,212,609
Ensembl chr 4:84,171,596...84,212,609
|
|
G |
Gas1 |
growth arrest-specific 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of GAS1 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr17:4,482,014...4,485,155
|
|
G |
Grhl2 |
grainyhead-like transcription factor 2 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of GRHL2 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 7:68,400,287...68,530,269
Ensembl chr 7:68,400,477...68,530,258
|
|
G |
Gucy1b1 |
guanylate cyclase 1 soluble subunit beta 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of GUCY1B1 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of GUCY1B1 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of GUCY1B1 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 2:167,348,824...167,398,983
Ensembl chr 2:167,348,825...167,398,916
|
|
G |
Gypa |
glycophorin A |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased mutagenesis of GYPA gene |
CTD |
PMID:17358027 |
|
NCBI chr19:27,450,311...27,465,940
Ensembl chr19:27,450,308...27,465,822
|
|
G |
Hadh |
hydroxyacyl-CoA dehydrogenase |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of HADH mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of HADH mRNA; [Zidovudine co-treated with Lamivudine] results in decreased expression of HADH mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 2:219,787,935...219,830,335
Ensembl chr 2:219,787,927...219,830,353
|
|
G |
Hadha |
hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of HADHA mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 6:26,187,969...26,227,605
Ensembl chr 6:26,187,956...26,227,869
|
|
G |
Hax1 |
HCLS1 associated protein X-1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of HAX1 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 2:175,434,242...175,437,926
Ensembl chr 2:175,434,238...175,437,714
|
|
G |
Hcn1 |
hyperpolarization-activated cyclic nucleotide-gated potassium channel 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of HCN1 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of HCN1 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of HCN1 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 2:49,495,771...49,899,702
Ensembl chr 2:49,495,771...49,899,774
|
|
G |
Hmgcs2 |
3-hydroxy-3-methylglutaryl-CoA synthase 2 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of HMGCS2 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 2:185,875,609...185,903,505
Ensembl chr 2:185,875,616...185,902,130
|
|
G |
Hrk |
harakiri, BCL2 interacting protein |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of HRK mRNA |
CTD |
PMID:16931933 |
|
NCBI chr12:38,387,484...38,409,652
|
|
G |
Hsd3b1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of HSD3B2 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 2:186,169,864...186,175,984
Ensembl chr 2:186,169,863...186,175,999
|
|
G |
Hsd3b3 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 3 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of HSD3B3 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 2:186,138,044...186,144,024
Ensembl chr 2:186,138,044...186,144,033
|
|
G |
Idh2 |
isocitrate dehydrogenase (NADP(+)) 2 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of IDH2 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025
|
|
G |
Idh3a |
isocitrate dehydrogenase (NAD(+)) 3 catalytic subunit alpha |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of IDH3A mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 8:54,971,694...54,991,085
Ensembl chr 8:54,971,740...54,991,084
|
|
G |
Idh3g |
isocitrate dehydrogenase (NAD(+)) 3 non-catalytic subunit gamma |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of IDH3G mRNA |
CTD |
PMID:18313992 |
|
NCBI chr X:151,515,244...151,524,175
Ensembl chr X:151,515,247...151,524,171
|
|
G |
Ifng |
interferon gamma |
increases expression |
ISO |
Lamivudine results in increased expression of IFNG protein |
CTD |
PMID:16250037 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Ikzf4 |
IKAROS family zinc finger 4 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of IKZF4 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of IKZF4 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of IKZF4 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 7:1,063,283...1,102,940
Ensembl chr 7:1,056,890...1,084,341
|
|
G |
Il27ra |
interleukin 27 receptor subunit alpha |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of IL27RA mRNA |
CTD |
PMID:15784690 |
|
NCBI chr19:24,109,698...24,121,977
Ensembl chr19:24,109,972...24,121,938
|
|
G |
Inpp5e |
inositol polyphosphate-5-phosphatase E |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of INPP5E mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 3:9,216,776...9,229,539
Ensembl chr 3:9,216,776...9,229,450
|
|
G |
Kcng1 |
potassium voltage-gated channel modifier subfamily G member 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of KCNG1 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 3:156,960,717...156,992,877
Ensembl chr 3:156,973,156...156,992,635
|
|
G |
Kifc2 |
kinesin family member C2 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of KIFC2 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 7:108,380,634...108,388,364
Ensembl chr 7:108,376,011...108,388,484
|
|
G |
Klf4 |
Kruppel like factor 4 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of KLF4 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 5:70,278,843...70,283,751
Ensembl chr 5:70,278,972...70,283,602
|
|
G |
Klhl28 |
kelch-like family member 28 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of KLHL28 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of KLHL28 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of KLHL28 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 6:82,987,360...83,018,971
Ensembl chr 6:82,990,945...83,016,164
|
|
G |